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Abstract
Human papillomavirus (HPV) is the most common sexually transmitted infection and the
leading cause of cervical cancer in the United States. Women from racial and ethnic
minorities with genital HPV are 2 to 3 times more likely to develop cervical cancer.
Vaccines are currently available to prevent HPV infections; however, despite their
effectiveness, national completion rates for these vaccines remain low among Hispanic
adolescents compared to non-Hispanic White adolescents. The reasons for this
racial/ethnic disparity are not fully understood. In this quantitative, cross-sectional study,
which was guided by the socioecological framework, the extent to which insurance
coverage and having a source of health care influenced completion of the HPV vaccine
series among Hispanic adolescent girls was examined. Nationally representative data
from the 2016 National Immunization Survey-Teen was analyzed. Results of multiple
logistic regression showed that gaps in insurance coverage did not adversely affect
completing the HPV vaccine series. Hispanic girls with continuous health insurance
coverage (p < .001) and girls who experienced gaps in health insurance coverage (p <
.001) were significantly more likely to complete the HPV vaccine series compared to
Hispanic girls who were uninsured. These results can be used to guide effective strategies
to increase HPV vaccination among Hispanic adolescents. Increasing the HPV vaccine
series completion rate among Hispanic adolescents has important implications for
positive social change, including decreasing their risk of infections, reducing the
prevalence of cervical cancers later in life, and decreasing the economic burden
associated with HPV infections among Hispanic women.
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Chapter 1: Introduction to the Study
Introduction
In the United States, genital human papillomavirus (HPV) is the most common
sexually transmitted infection (STI) affecting men and women (Centers for Disease
Control and Prevention [CDC], 2017). The infection is so common that individuals who
are sexually active have a 75% chance of being infected with HPV at some point in their
lifetimes (CDC, 2017; Tota, Chevarie-Davis, Richardson, DeVries, & Franco, 2011;
Valentino & Poronsky, 2016). In the United States alone, approximately 80 million
people are infected with HPV, and each year, 14 million newly infected cases are
diagnosed, with 50% of the cases occurring in persons 15 to 24 years of age (CDC, 2017;
Tota et al., 2011; Valentino & Poronsky, 2016).
In most cases, the infection is cleared within 2 years by the body’s immune
system, but persistent infection with high-risk HPV serotypes (e.g., HPV 16 and 18) can
lead to cervical, anal, penile, vaginal, vulvar, and oropharyngeal cancers later in life
(CDC, 2017; Nickel et al., 2017; Pahud & Ault, 2015). Likewise, persistent infection
with low-risk serotypes (e.g., HPV 6 and 11) can lead to the development of genital warts
in adolescents (CDC, 2017; Nickel et al., 2017; Pahud & Ault, 2015). More than 33,000
HPV-related cancers are diagnosed annually, and approximately 62% of these cases are
among women (CDC, 2017; Lai et al., 2017; Markowitz et al., 2014). Moreover, 70% of
cervical cancers and 90% of genital warts in women are HPV related (CDC, 2017).
Prior to 2006, prevention of cervical cancer was limited to secondary preventative
measures like early detection with the Papanicolau (Pap) test (González, Suárez, & Ortiz,
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2015; Thomas, 2016). The Pap test is a safe, noninvasive, and inexpensive procedure
used for detecting abnormal cells that might lead to cancer if left untreated; however,
most women who are diagnosed with cervical cancer have never been screened for the
disease (Glick, Clarke, Blanchard, & Whitaker, 2012; McKeever, Bloch, & Marrell,
2015). In the United States, racial and ethnic minority women and women from a lower
socioeconomic status are 2 to 3 times more likely to develop cervical cancer because of
persistent infection with genital HPV and are less likely to have a Pap test (American
Cancer Society [ACS], 2017; Lechuga, Vera-Cala, & Martinez-Donate, 2016). For
example, even though Hispanic women tend to have a higher incidence of cervical
cancer, they are less likely to be screened for HPV-related cancers compared to African
Americans and other non-Hispanic women (ACS, 2017; Lechuga et al., 2016; Roncancio,
Ward, Carmack, Muñoz, & Cribbs, 2017). In fact, each year, approximately 2,000
Hispanic women are diagnosed with cervical cancer, and about 600 of them die from the
disease (ACS, 2017).
Three vaccines against HPV are currently available, and although these vaccines
do not treat existing infection, they are effective in preventing vaccine-specific HPV
infections in adolescents and young adults (CDC, 2017; Dunne et al., 2014; Markowitz et
al., 2014; Yang, Farmer, Wu, & Hung, 2016). To harness the full potential of these
vaccines, all recommended doses should be administered before exposure to HPV (i.e.,
before engaging in sexual intercourse; Markowitz et al., 2014; Tota et al., 2011;
Valentino & Poronsky, 2016). Receipt of the vaccine series before sexual debut is
imperative because it is estimated that vaccinating young girls not only reduces the
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prevalence of HPV by 64% but also can reduce the incidence of cervical cancer by
greater than 90% (Markowitz et al., 2016; Roncancio et al., 2016). Per the Advisory
Committee for Immunization Practice (ACIP), girls as young as 9 years of age through to
12 years of age should be vaccinated against HPV (CDC, 2017; Markowitz et al., 2014).
Three doses of the vaccine are recommended as a routine vaccination for girls 11
to 12 years of age (CDC, 2017). For individuals 13 to 26 years of age who have not been
vaccinated or who have not completed the vaccine series, catch-up vaccination is
recommended (CDC, 2017). However, despite the effectiveness of the vaccines and the
ACIP’s recommendation for HPV vaccination, national rates of completing the vaccine
series remain low (CDC, 2017; Markowitz et al., 2014). Nationally, less than 50% of
adolescent girls 13 to 17 years of age had received all three doses of the vaccine (CDC,
2017; Markowitz et al., 2014).
The percentage of adolescent girls who have completed the vaccine series varies
by state, and from one state to another, this percentage has tended to be much lower
among racial/ethnic minority girls (Jeudin, Liveright, del Carmen, & Perkins, 2014;
Markowitz et al., 2014; Thompson, Rosen, Vamos, Kadono, & Daley, 2017). Adolescent
Hispanic girls have higher rates than non-Hispanic White girls of initiating the vaccine
series (Kepka, Ding, Bodson, Warner, & Mooney, 2015; Roncancio et al., 2017; Walker
et al., 2017). However, Hispanic girls are less likely than non-Hispanic Whites or girls
from other racial and ethnic minority groups to complete the vaccine series (Kepka, Ding,
Bodson, Warner, & Mooney, 2015; Roncancio et al., 2017; Walker et al., 2017).
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Although completing the vaccine series is crucial for all girls (CDC, 2017; Kepka
et al., 2015), it is more important for Hispanic girls, given the high incidence of cervical
cancer in this population (Kepka et al., 2015). However, administering the vaccine to
racial and ethnic minorities could be challenging because these adolescents are less likely
to have access to preventive care services and are more likely to receive low-quality
health care (Gelman et al., 2013; Polonijo & Carpiano, 2013). They are also less likely to
have permanent medical homes and are more likely to be underinsured or uninsured
(Jarlenski, Baller, Borrero, & Bennett, 2016; G. K. Singh, Rodriguez-Lainz, & Kogan,
2013). Adolescents from racial and ethnic minority groups are also less likely to have at
least one well-care visit per year (Gelman et al., 2013; Velasco-Mondragon, Jimenez,
Palladino-Davis, Davis, & Escamilla-Cejudo, 2016). Because health care providers must
administer the vaccine, having limited access to preventive services might prevent
minority girls from completing the vaccine series.
I undertook this study to assess the extent to which having continuous health
insurance coverage as well as a source of health care influenced completion of the HPV
vaccine series among Hispanic female adolescents. Relative to the study, the implications
for positive social change include informing guidelines and public health policies that
support continuous access to preventive care services, regardless of insurance status.
Reducing disparities in insurance coverage also could help to increase the uptake and
completion of the HPV vaccine series among Hispanic adolescent girls. Boosting the
completion rate of the vaccine series has the potential to reduce the risk of HPV infection
among adolescent girls who are sexually active. Ultimately, there is the potential to
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reduce the prevalence of HPV-related cervical cancer, which could then decrease the
economic burden associated with HPV infection among Hispanic women.
Included this chapter is a summary of the literature pertaining to the current study,
the research problem that was addressed, the purpose and nature of the study, and the
research questions and hypotheses that guided this study. In this chapter, I will also
provide the theoretical framework or conceptual foundation of the study; definitions of
key terms and concepts related to the study; the limitations, scope, delimitations, and
assumptions of the study; and the significance of the study. The chapter closes with a
summary of the key points made in the chapter and a transition to Chapter 2.
Background of the Study
Prevalence of HPV infection tends to peak shortly after the onset of sexual
activity (CDC, 2017; Pahud & Ault, 2015). Comparatively, this prevalence correlates
with the rate of infection among adolescent girls and young female adults, who tend to
have a disproportionately higher rate of infection than women in other age groups (Bosch
et al., 2013; Gamble, Klosky, Parra, & Randolph, 2010; Valentino & Poronsky, 2016).
Most HPV infections are asymptomatic (Pahud & Ault, 2015). In 90% of HPV infections,
the infection is resolved by the immune system within 2 years (Guerra-Rodríguez,
Champion, Morano-Monsivais, Olivares-Ornelas, & Vazquez, 2017; Pahud & Ault,
2015). For the remaining 10% of HPV infections, the infection will persist and can result
in the development of HPV-related cervical cancer or genital warts (Cokkinides, Bandi,
Siegel, & Jemal, 2012; Valentino & Poronsky, 2016).
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Despite the effectiveness of the vaccines in preventing HPV infection, Hispanic
girls are less likely than non-Hispanic White girls or girls from other racial and ethnic
minority groups to complete the HPV vaccine series (Kepka et al., 2015; Roncancio et
al., 2017; Walker et al., 2017). Data from a 2014 national survey showed that among
Hispanic adolescents, 66.3% of girls initiated the series but only 48.3% completed the
three-dose series (Jemal et al., 2013). At the state level, the HPV vaccine initiation rate
among Hispanic girls 13 to 17 years of age living in Texas has been reported as 55%,
with only 39.3% completing the series (Jemal et al., 2013). Despite having higher rates of
initiating the vaccine series, adolescent girls from racial and ethnic minority groups (e.g.,
Blacks and Latinas), from low-income families, and who are publicly insured have been
shown to be consistently less likely to complete the vaccine series when compared to
their affluent and privately insured White counterparts (Chou, Krill, Horton, Barat, &
Trimble, 2011; Jeudin et al., 2014; Niccolai, Mehta, & Hadler, 2011).
As the primary caregivers, Hispanic mothers are likely to have their daughter(s)
vaccinated against HPV if they perceive that the vaccine is beneficial, safe, and
affordable, and if their health care providers recommend the vaccine series (Ashting,
Chávez, & Serrano, 2016; Berenson, 2015; Brown, Gabra, & Pellman, 2017). Gaining
consent from the mothers is crucial to the likelihood of their daughters completing the
vaccine series (Ferrer, Trotter, Hickman, & Audrey, 2014). However, the mothers’
consent is dependent on other factors, such as characteristics of the subjects in question
(i.e., girls’ ages); concerns that the vaccine promotes sexual promiscuity; and awareness
and knowledge of HPV, the vaccines, and HPV-related diseases (Dorell, Yankey,
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Santibanez, & Markowitz, 2011; Ferrer et al., 2014; Laz, Rahman, & Berenson, 2012;
Perkins, Brogly, Adams, & Freund, 2012; Thompson, Best, Vamos, & Daley, 2017).
Other factors, such as being able to afford the vaccine, having health insurance, and
having access to preventive services, also can affect the likelihood of daughters
completing the vaccine series (Gerend, Zapata, & Reyes, 2013; Roncancio et al., 2016,
2017). However, there continues to be a lack of knowledge about the impact of insurance
coverage and accessibility of preventive services on completing the HPV vaccine series. I
filled a gap in the literature with this study by assessing the ways that continuity in
insurance coverage and access to preventive services influenced completion of the HPV
vaccine series among Hispanic girls.
Hispanics encounter many challenges that shape the conditions in which they live
and affect their overall health and well-being (Velasco-Mondragon et al., 2016). They are
more susceptible to being less educated, having limited access to health care services,
having a lower socioeconomic status, and being underinsured (Velasco-Mondragon et al.,
2016). Subsequently, Hispanic adolescents living in certain communities across the
United States might be misinformed about the efficacy and safety of the HPV vaccines
and might have limited access to preventive care services (Katz et al., 2016). Relative to
the cost of the vaccine, these individuals might not have insurance and might not know
about the Vaccine for Children Program, which provides the vaccine at no cost to
individuals who are underinsured or uninsured (Reiter et al., 2014).
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Problem Statement
Racial and ethnic disparities in HPV vaccination are likely due to a combination
of different factors. Disparities in insurance coverage have been shown to affect access to
and utilization of health care and also might be contributing to disparities in the health of
Hispanic children (DeCamp & Bundy, 2012). Efforts have been made over the years to
increase insurance coverage and to make health care more accessible to Hispanics
(DeCamp & Bundy, 2012). However, many eligible Hispanic adolescents are less likely
to be enrolled, and if enrolled, they are more likely to experience the effects of
discontinuity in health insurance coverage (DeCamp & Bundy, 2012; DeVoe, Tillotson,
Angier, & Wallace, 2015; Gelman et al., 2013).
Insurance coverage is crucial to the uptake of the vaccine because research has
shown that initiation of the vaccine series is the lowest among girls who are uninsured
(Reiter et al., 2014), yet very little is known about the impact of discontinuous insurance
coverage on completing the HPV vaccine series. The HPV vaccine is administered over a
6-month period: baseline (0 months), 2 months, and 6 months; however, not everyone
follows this schedule (Widdice, Bernstein, Leonard, Marsolo, & Kahn, 2011). Some girls
might take longer to complete the vaccine series. During this time, individuals’ insurance
status might change (e.g., they might be without health insurance for a period of time,
making it unlikely that they will complete the vaccine series; Cowburn, Carlson, &
Lapidus, 2014). Few researchers have investigated the association between insurance
continuity and completion of the vaccine series, and studies assessing the relationship
between insurance coverage and completion of the vaccine series have yielded mixed
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results (Cowburn et al., 2014; Federico, Abrams, Everhart, Melinkovich, & Hambridge,
2010; Tiro et al., 2012). The results of these studies were inconclusive and were further
complicated by differences in how insurance status was measured. Furthermore, most
researchers have tended to assess insurance coverage at a single point in time (Cowburn
et al., 2014; Federico et al., 2010; Tiro et al., 2012). The issue with measuring insurance
coverage at a single point in time is that it is difficult to assess how lapses in insurance
coverage affect completing the vaccine series.
With this study, I sought to assess the influence of insurance coverage on HPV
vaccine rates for adolescents. More specifically, I explored the extent to which gaps in
insurance coverage influenced completion of the vaccine series for a nationally
representative sample of Hispanic adolescents. Because health insurance increases the
likelihood of accessing different types of health care facilities, the impact of insurance
coverage and source of health care on completion of the HPV vaccine series were also
assessed.
With programs like the Children Health Insurance Program, children can be
insured regardless of the insurance status of their parents (DeVoe et al., 2016). However,
although poorly understood, parental insurance coverage influences the likelihood of the
children being continuously insured (DeVoe et al., 2015, 2016). Whether covered by
private or public insurance, DeVoe et al. (2016) showed that the insured children of
insured parents, in comparison to the insured children of uninsured parents, have a lower
chance of experiencing gaps in insurance coverage. Understanding how fluctuations in
insurance coverage affected the use of preventative services was important in identifying
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new guidelines that can be implemented to boost HPV vaccination coverage among highrisk populations.
Purpose of the Study
The purpose of this quantitative study was to assess the relationship between
discontinuity in insurance coverage, the type of medical facility used for health care, and
HPV vaccination among Hispanic girls. The dependent variable in the study was HPV
vaccination status (i.e., being fully vaccinated or not fully vaccinated), and the
independent variables were insurance coverage (i.e., insurance status of the adolescent)
and type of medical facility used to access health care. Covariates included maternal age,
family income, maternal education, and health care provider recommendation to get the
HPV vaccine series.
I measured the dependent variable, HPV vaccination status, as a dichotomous
variable. The independent variables, insurance coverage and type of medical facility,
were measured as nominal variables. The covariates, maternal age and family income,
were measured as continuous variables; maternal education was measured as an ordinal
variable; and health care provider recommendation was measured as a nominal variable.
Research Questions and Hypotheses
The study was guided by the following three research questions and the
corresponding hypotheses:
Research Question 1: Is there a statistically significant relationship between health
insurance coverage and the HPV vaccination status of Hispanic girls?
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H01: There is no statistically significant association between health insurance
coverage and the HPV vaccination status of Hispanic girls.
Ha1: There is a statistically significant association between health insurance
coverage and the HPV vaccination status of Hispanic girls.
Research Question 2: Is there a statistically significant relationship between the
type of medical facility used to access health care and the HPV vaccination status of
Hispanic girls?
H02: There is no statistically significant association between the type of medical
facility used to access health care and the HPV vaccination status of Hispanic girls.
Ha2: There is a statistically significant association between the type of medical
facility used to access health care and the HPV vaccination status of Hispanic girls.
Research Question 3: Is there a statistically significant relationship between health
insurance coverage, the type of medical facility used to access health care, and the
likelihood of completing the HPV vaccine series?
H03: There is no statistically significant association between health insurance
coverage, the type of medical facility used to access health care, and the likelihood of
completing the HPV vaccine series.
Ha3: There is a statistically significant association between health insurance
coverage, the type of medical facility used to access health care, and the likelihood of
completing the HPV vaccine series.
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Theoretical Background
I based this study on the tenets of the socioecological model (SEM), which was
used to explain the relationship between individuals’ health and their environments.
Based on the assumption that health is the result of several factors, the SEM theorizes
that the social and physical environments, as well as organizational factors, policies, and
regulations, interact to determine the health and health behaviors of individuals (Baral,
Logie, Grosso, Wirtz, & Beyrer, 2013; Paat, 2013). The SEM is the culmination of the
work of Bronfenbrenner (1977); McLeroy, Bibeau, Steckler, and Glanz (1988); Stokols
(1992; and Stokols, Grzywacz, McMahan, & Phillips, 2003). Bronfenbrenner’s
ecological systems theory emphasized the relationship between individuals and their
environments; McLeroy et al.’s ecological model of health behaviors highlighted the
different levels of influence on health behaviors; and the social ecological model of
health promotion (Stokols, 1992; Stokols et al., 2003) outlined the assumptions that
support the SEM (Baral et al., 2013; Nyambe, Van Hal, & Kampen, 2016).
As shown in Figure 1, the SEM is divided into five levels of influence that
determine health outcomes or reduce risks to given health outcomes: (a) individualrelated factors or intrapersonal factors, (b) interpersonal factors, (c) organizational-related
factors, (d) community-level factors, and (e) public policy-level factors (Baral et al.,
2013; Chimphamba-Gombachika et al., 2012). Individual-related factors are based on
characteristics of the individual (i.e., beliefs, attitudes, and knowledge; Baral et al., 2013;
Chimphamba-Gombachika et al., 2012). Interpersonal factors refer to individuals’ social
groups or networks (i.e., family members, friends, spouses/partners, health care
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providers; Baral et al., 2013; Chimphamba-Gombachika et al., 2012). Organizationalrelated factors are formal or informal factors, such as rules and regulations, that regulate
the operations of social institutions or organizations (Baral et al., 2013; ChimphambaGombachika et al., 2012). Community-level factors relate to the relationships between
and among different entities (i.e., local, state, national, and federal), and public policylevel factors relate to national, state, and local health laws and policies (Baral et al., 2013;
Chimphamba-Gombachika et al., 2012).

Figure 1. Socioecological model. Adapted with modifications from “The social
ecological model: A framework for prevention,” by CDC, 2015a. Retrieved from
http://www.cdc.gov/violenceprevention/overview/social-ecologicalmodel.html
I selected the SEM to understand the different determinants of a given health
behavior, such as vaccine usage, and how these determinants interact to influence the
decision to engage in such behavior. For example, as shown in Figure 2, Hispanic

14
mothers’ perceptions of the susceptibility of their children to HPV-related diseases, the
barriers to accessing the vaccine, and the perceived benefits of the vaccine might
influence their decision to vaccinate their children against HPV. Likewise, their decision
to accept the HPV vaccine is shaped by their social networks, the recommendation of
health care providers, accessibility of health care facilities used for HPV health-related
issues, and the availability of the vaccine at these locations. The mothers’ decision to
vaccinate their daughters against HPV also is affected by their perceptions of the risk of
HPV based on community levels of the disease, the financial cost of obtaining the
vaccine, health coverage, whether state policy mandates HPV vaccine for school entry,
and whether state-level regulations support the availability of HPV-related educational
materials that are culturally appropriate (Fernandez, Allen, Mistry, & Kahn, 2010;
Nyambe et al., 2016).
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Figure 2. Socioecological framework for HPV vaccine uptake. Adapted with
modifications from “Screening and Vaccination As Determined by the Social Ecological
Model and the Theory of Triadic Influence: A Systematic Review,” by A. Nyambe et al.,
2016, BMC Public Health, 16, p. 1166. Copyright 2016 by the A. Nyambe et al. Adapted
with permission.
Nature of the Study
I employed a quantitative, cross-sectional design in this study. I analyzed
secondary data from the 2016 National Immunization Survey-Teen (NIS-Teen; CDC,
2016a) to assess the relationship between insurance coverage, the type of medical facility
used to access health care, and completion of the HPV vaccine series among Hispanic
girls. After downloading and cleaning the data, I used logistic regression to determine the
significance of the relationship between health insurance coverage, the type of medical
facility used to access health care, and completion of the HPV vaccine series among
adolescent Hispanic girls.
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Operational Definitions
Discontinuity in health insurance coverage: Having a lapse or disruption in
insurance coverage. This includes individuals who are currently insured but were
uninsured at some point, individuals who are currently uninsured but were insured at
some point, and individuals who are currently insured and never uninsured (CDC,
2016b). This definition also includes individuals who are currently uninsured and were
never insured.
Insurance coverage: Having insurance coverage, whether private or public health
insurance (CDC, 2016b).
Type of medical facility: The facility an individual used to access their primary
care provider. This includes public health-operated clinics, hospital-based clinics, or
private practice (CDC, 2016b).
Vaccination status: Whether girls are fully vaccinated with the recommended
HPV vaccines (CDC, 2016b). A “no” response indicates that they were not vaccinated,
and a “yes” response indicates that they had received at least one dose of the HPV
vaccine series.
Assumptions of the Study
I made several key assumptions in this study. The first assumption was that the
instrument used to collect the data was valid and reliable based on its use in other HPV
vaccination studies. Another assumption was that the collected data were free of any
interviewer bias. I also assumed that the collected data were truthful based on the
knowledge and ability of the respondents.
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Scope and Delimitations
The focus of the study was on adolescent Hispanic girls, so the findings cannot
be generalized to all adolescent girls. Relative to completing the vaccine series, I focused
only on the HPV vaccine in girls in this study; therefore, the findings cannot be
generalized to boys and other multidose vaccines. The collected data were limited to the
responses given by the responding parents or guardians, who determined the eligibility of
the adolescents present in the household and provided all information pertaining to the
adolescents. The NIS-Teen collected data only on adolescents living in the United States
and select territories at the time of the interview.
Limitations of the Study
The study was subject to several limitations inherent in the use of secondary data.
In using archival NIS-Teen data, this study was restricted to questions asked in the survey
and was limited to the definitions, values, and nature of the variables in the NIS-Teen
data set. The NIS-Teen data set contains provider-verified HPV vaccination information;
however, self-reported demographics and other relevant information also might have led
to an overestimation or underestimation of the variables in question. Given the propensity
for bias with self-reported information, this bias could have affected the true nature of the
relationship between these factors and completion of the HPV vaccine.
Significance of the Study
The higher the rate of the HPV vaccine series completion is among adolescents,
the more likely is the chance of reducing the risk of HPV-related disease later in
adulthood (Wisk, Allchin, & Witt, 2014). Access to a source of health care and insurance
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coverage are both integral to this process, so it was important that any potential barriers
related to these constructs be identified and disseminated. Relative to positive social
change, alleviating issues with the source of health care accessed and insurance coverage
could help to increase the completion rate of the HPV vaccine series (Lu et al., 2018). In
turn, boosting the vaccine series completion rate could reduce not only the risk of HPVrelated infection but also the prevalence of cervical cancer and, ultimately, decrease the
economic burden associated with HPV infection among Hispanic women.
Summary
In this chapter, I introduced insurance coverage, discontinuity in health insurance
coverage, and source of health care as potential contributors to the disparity in
completion of the HPV vaccine by adolescent Hispanic girls. Completing the HPV
vaccine series is crucial for all girls, but for Hispanic girls, it is more important given the
high incidence of cervical cancer among Hispanic female adults (Kepka et al., 2015).
Administering the vaccine to adolescents from racial and ethnic minority groups is
challenging because they are more likely to have limited access to preventive care
services and be underinsured than to be continuously insured (Katz et al., 2016; Reiter et
al., 2014). They also are less likely to have permanent medical homes and at least one
well-care visit per year (Gelman et al., 2013; Velasco-Mondragon et al., 2016). Because
health care providers are essential to administering the HPV vaccine series, discontinuous
insurance coverage and limited access to a source of health care have the potential to
interfere with completion of the vaccine series.
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Employing a quantitative study design, I assessed the extent to which insurance
coverage and the type of medical facility used to access health care affected the
likelihood of Hispanic adolescent girls completing the HPV vaccine series in this study.
Insurance coverage and having a source of health care might not resolve the issue of the
underutilization of the HPV vaccine among Hispanic adolescents across the United
States, but these constructs might help to highlight areas that can be targeted when
formulating guidelines and policies that will aid in increasing the uptake of the HPV
vaccine among this ethnic group. In Chapter 2, I will present a detailed discussion of the
theoretical foundation of the study, the literature search strategy, and a review of the
literature, with an emphasis on gaps in insurance coverage and immunizations among
Hispanic girls living in the United States.
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Chapter 2: Literature Review
Introduction
Increasing the completion rate of the HPV vaccine series among adolescent girls
has the potential to significantly reduce the prevalence and mortality rate of cervical
cancer later in life (Valentino & Poronsky, 2016). Despite the effectiveness of the HPV
vaccine and the ACIP’s recommendation for vaccinations (Fishman, Taylor, & Frank,
2016; Vielot, Butler, Brookhart, Becker-Deps, & Smith, 2017), completion of the vaccine
series continues to be low among adolescent girls. HPV vaccine completion among girls
varies by age (Niccolai et al., 2011); state (Walker et al., 2017); race and ethnicity (Wisk
et al., 2014); and socioeconomic status (Wisk et al., 2014). It also varies by insurance
status and by the recommendation made, or not made, by health care providers to have
the vaccine series (Gilkey et al., 2016; Jarlenski et al., 2016).
Completing this review of the literature was relevant to gaining a better
understanding of the factors contributing to disparities in completing the HPV vaccine
series. In Chapter 2, I provide an explanation of the ways that the SEM can be used as a
framework to understand the reasons for the low completion rate of the HPV vaccine
series. I present an overview of HPV, HPV-related diseases, and the HPV vaccines
currently available to prevent HPV-related diseases. I also present a review of the
literature relative to the continuity of insurance coverage and other barriers to the uptake
of the vaccine. The chapter concludes with a discussion of the ways that gaps in
insurance coverage and racial and ethnic disparities influence the uptake of the vaccine
among Hispanic adolescent girls.
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Literature Search Strategy
I conducted a comprehensive literature review to identify research on insurance
continuity, HPV vaccine disparities, and racial and ethnic disparities and HPV vaccine
completion among adolescents. The databases used in the search for relevant literature
included Google Scholar, PubMed, MEDLINE, APA PsycNET, EBSCOhost, CINAHL,
and Science Direct. I gathered additional resources from ProQuest Theses and
Dissertations database and the U.S. National Library of Medicine. The key search terms
used either in combination or isolation to locate peer-reviewed articles were insurance,
insurance coverage, private insurance, public insurance, gaps in insurance, discontinuity
in insurance, continuous insurance, vaccination, racial and ethnic minorities, human
papillomavirus (HPV), HPV vaccine, HPV vaccination initiation and completion, HPV
vaccine and insurance, vaccine-preventable diseases, cervical cancer prevention, Latino
health, immigrants and HPV, immigrants’ health, African American health, HPV risk
perception, health care facilities, preventive service, health care, well-care visit, provider
recommendation, socioecological model, adolescents’ health, adolescents’ health
disparity, and adolescents’ vaccines. Relative to this study, I set the limit to research
articles published within the last 5 years in most databases, and as deemed necessary, I
extended the limit to 10 years in other databases. I sought articles published between 10
and 20 years ago based on their relevance to more recent literature and the current study.
Relatedly, the number of publications addressing insurance coverage continuity as a
factor in vaccination completion was limited; therefore, I expanded the scope of the
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search to include as many studies as possible based on their relevance to the topic of
interest.
Theoretical Foundation
Socioecological Model
This study was framed by the perspectives of the SEM, which is based on
Bronfenbrenner’s (1977) ecological systems theory; McLeroy et al.’s (1988) ecological
model of health behaviors; and the social ecological model of health promotion (Stokols,
1992; Stokols et al., 2003). The SEM posits that five levels of influence determine
behavior: (a) intrapersonal or individual characteristics such as beliefs, knowledge and,
attitudes; (b) interpersonal factors; (c) organizational/institutional factors; (d) communityrelated factors; and (e) societal level factors or public policies factors. (Baral et al., 2013;
Chimphamba-Gombachika et al., 2012; Nyambe et al., 2016; Paat, 2013; Schölmerich &
Kawachi, 2015). Figure 3 shows the interconnection between these factors and the ways
that they influence each other to determine the uptake of the HPV vaccine (see Lanning,
Golman, & Crosslin, 2017).

23

Figure 3. Socioecological model of factors influencing HPV vaccination. Adapted from
“Improving Human Papillomavirus Vaccination Uptake Among College Students: A
Socioecological Perspective,” by B. Lanning, M. Golman, & K. Crosslin, 2017,
American Journal of Health Education, 48(2), p. 118. Copyright 2018 by Copyright
Clearance Center. Adapted with permission.
Individual or intrapersonal factors are based on characteristics that influence
given health behaviors. In this case, the characteristics of the mothers and the daughters
affect completion of the HPV vaccine series (Fernandez et al., 2010; Ferrer, Audrey,
Trotter, & Hickman, 2015). These characteristics include maternal acceptance of the
vaccine and willingness to vaccinate their daughters against the virus (Fernandez et al.,
2010; Ferrer, Audrey, et al., 2015). Maternal acceptance of the vaccine depends on the
mothers’ ages and beliefs, attitudes, and knowledge about HPV and the HPV vaccines
(Fernandez et al., 2010; Ferrer, Audrey, et al., 2015). It also depends on maternal
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socioeconomic status, educational attainment, level of health literacy, and level of
acculturation if they are immigrants (Ciampa et al., 2012; Kepka et al., 2015; Walter,
Murphy, Frank, & Baezconde-Garbanati, 2017; Wisk et al., 2014). As for adolescents,
their ages, what they know about HPV and the vaccines, and whether their friends have
or have not received the vaccine can influence their receipt of the vaccine (Fernandez et
al., 2010; Ferrer, Audrey, et al., 2015). The decision to vaccinate or get the vaccine is
also influenced by the risk perceptions of mothers and daughters, their perceptions of
susceptibility to the infection, severity of the disease, and perceived benefits of the
vaccine to protect against the infection or cervical cancer (Fernandez et al., 2010; C. E.
Hansen, Credle, Shapiro, & Niccolai, 2016).
Interpersonal factors refer to the people in an individuals’ social networks or
support groups who could influence receipt and completion of the vaccine series
(Fernandez et al., 2010; Ferrer, Audrey, et al., 2015; Lanning et al., 2017). Among these
sources of influence are family members, friends, health care providers, and spouses or
partners (Lanning et al., 2017). Social influence is a known predictor of the uptake of the
vaccine (Fernandez et al., 2010; Ferrer, Audrey, et al., 2015). For example, if mothers
believe that their friends and family members approve of vaccinating young girls against
HPV, they are more likely to have their daughters vaccinated against HPV (Fernandez et
al., 2010; Ferrer, Audrey, et al., 2015). Likewise, if their health care providers
recommend the vaccine, mothers are more likely to have their daughters vaccinated
(Gilkey, Malo, Shah, Hall, & Brewer, 2015; Warner et al., 2017). Relative to the
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daughters, if they perceive that their mothers approve of getting the vaccine, it will
increase their chances of being vaccinated (Warner et al., 2017).
Organizational or institutional factors are formal or informal rules and regulations
that regulate the availability of the HPV vaccine. In the United States, the U.S. Food and
Drug Administration (FDA, 2018) approves the vaccine. The ACIP recommends the
vaccine, decides who should be vaccinated, at what age, and how often the vaccine
should be administered (CDC, 2016e). Vaccine manufacturers, commercial distributors,
and state and local governments work together to develop or improve existing
infrastructure to deliver the HPV vaccine series (Fernandez et al., 2010; Markowitz et al.,
2012; Shefer et al., 2012). Relative to the cost of the vaccine, public and private entities
work together to make the vaccine more accessible (CDC, 2015b, 2018). However, at this
level, the lack of an established adolescent vaccination program and the lack of a clear
plan to maximize the uptake of the vaccine series also influence the HPV vaccine
completion rate (Fernandez et al., 2010; Ferrer, Audrey, et al., 2015).
Community-level factors refer to local, state, national, and federal governing
bodies that influence the uptake of the HPV vaccine. The cost of the vaccine affects its
uptake (Fernandez et al., 2010; Ferrer, Trotter, Hickman, & Audrey, 2015; Warner et al.,
2017). The HPV vaccine is one of the most expensive vaccines available (CDC, 2015b,
2018). For individuals with private or public insurance, the vaccine is covered by most
private insurance plans and is available at no cost for individuals who are publicly
insured; however, not all adolescents have private insurance or are eligible for federal or
state-level programs that cover the cost of the vaccine (Lindley, Smith, & Rodewald,
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2011). Also, not everyone without insurance can afford to pay for the vaccine themselves.
Therefore, the lack of insurance and the lack of financial means to cover the cost of the
vaccine mean that completion of the vaccine series is highly unlikely (Fernandez et al.,
2010; Ferrer, Trotter, et al., 2015).
The final level of influence encompasses public policies. These national, state,
and local health laws and policies not only govern but also affect vaccine uptake. These
policies include ordinances at the state and federal levels that make the vaccine
mandatory for school entry or entrance into the United States (Fernandez et al., 2010).
The policies also include mandates for increasing the availability of educational tools at
clinics, schools, doctors’ offices, and so on (Fernandez et al., 2010). Raising awareness of
and increasing knowledge about HPV and the HPV vaccines are instrumental to the
receipt and completion of the vaccine series (Lai et al., 2017). However, making the
vaccine mandatory is controversial, and only a few states have succeeded in making HPV
vaccination mandatory for school entry (Fernandez et al., 2010). Mandating the vaccine
for school entry could be more of a hindrance than a facilitator of the uptake of the
vaccine (Fernandez et al., 2010).
Three groups of researchers have attempted to explain the uptake of the HPV
vaccine using an integrated model based on the tenets of the SEM (Downs, Scarinci,
Einstein, Collins, & Flowers, 2010; Fernandez et al., 2010; Ferrer et al., 2014). To
identify the factors that inhibit or facilitate uptake of the HPV vaccine among young
women, Ferrer et al. (2014) employed a systematic approach and found that parents,
health care providers, and policymakers drove receipt of the HPV vaccine among young
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women. Factors that negatively influenced the uptake of the vaccine included the cost of
the vaccine, lack of health care provider recommendation, and cultural and religious
values (Ferrer et al., 2014). Therefore, although health care providers and policymakers
can have a positive effect on uptake of the vaccine, the lack of health care provider
recommendations and religious values both can have a negative effect on the uptake of
the vaccine.
To maximize the uptake of the HPV vaccine among high-risk adolescents, a
multilevel approach is needed (Downs et al., 2010). According to Downs et al. (2010),
this approach takes into consideration all levels of influence, beginning with individualrelated factors and continuing with factors related to social networks, organizationalrelated factors, community, and public policies. Because this multilevel approach is more
holistic, it is useful and more realistic as a foundation for improving uptake of the
vaccine. Fernandez et al. (2010) also showed that personal as well as external factors,
such as interpersonal, organizational, community and societal-related factors influence
the intent to vaccinate against HPV as well as the acceptability of the vaccine. Moreover,
Fernandez et al. posited that employing a multilevel approach to address issues with the
uptake of the HPV vaccine series would likely enhance its uptake, unlike approaches that
target a single factor like maternal attitudes.
Justification for Using the Socioecological Model
The health belief model (HBM; Hochbaum, 1958; Rosenstock, Strecher, &
Becker, 1988); the theory of planned behavior (TPB; Ajzen, 1991; Ajzen & Madden,
1986); and the theory of reasoned action (TRA; Fishbein & Ajzen, 1977, 1980) are the
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most commonly used theoretical approaches to explain behaviors among adolescents
relevant to the HPV vaccine. However, the problem with the use of these models is that
they capture only the psychological factors that affect the decision to accept the vaccine
or the intent to have daughters vaccinated against HPV. The HBM, for example, offers
six psychological factors that predict the likelihood of mothers allowing their daughters
to be vaccinated against HPV: susceptibility to HPV (perceived susceptibility); severity
of the disease (perceived severity); benefits of the vaccine (perceived benefits); barriers
to obtaining the vaccine (perceived barriers); self-efficacy (i.e., mothers’ belief in their
ability to act on information about the vaccine and HPV-related diseases); and call to
action (i.e., having daughters complete the vaccine series; Bowyer, Forster, Marlow, &
Waller, 2014; Morales-Campos, Markham, Peskin, & Fernandez, 2013; Spleen,
Klushman, Clark, Dignan, & Lengerich, 2012).
The basic tenet of the TRA is that the intention to act on given cues is determined
by behaviors (Fishbein & Ajzen, 1977, 1980). This intention is determined by two key
elements, namely, attitudes toward the behaviors in question and subjective norms toward
such behaviors (Fishbein & Ajzen, 1977, 1980). Subjective norms are individuals’
perceptions of what others think about their adopting the behaviors in question (Fishbein
& Ajzen, 1977, 1980). Relative to HPV vaccination, researchers have used the TRA to
predict or identify the factors that influence mothers’ intentions to have their daughters
vaccinated against HPV (Natan, Aharon, Palickshvili, & Gurman, 2011; Reynolds &
O’Connell, 2012) and to predict which elements influence health care providers to
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recommend the HPV vaccine to the mothers of adolescent daughters (Roberto, Krieger,
Katz, Goei, & Jain, 2011).
The TPB is an extension of the TRA (Ajzen, 1991; Ajzen & Madden, 1986).
Because individuals might have little control over some behaviors, the TPB posits that
individuals’ perceived control over given behaviors influences the intention to perform
the behaviors in question (Ajzen, 1991; Ajzen & Madden, 1986). Concerning the HPV
vaccine, researchers have used the TPB to assess mothers’ intentions to talk to their
daughters about sex, HPV, and other HPV-related matters relative to the vaccine
(Askelson et al., 2011b). It has been used to assess adolescents’ psychosocial factors that
predict the likelihood of their being vaccinated against HPV (Bowyer et al., 2014) and to
assess health care providers’ intentions to talk to young women about sex-related matters
and the HPV vaccines (Askelson et al., 2011a).
Theories have been used to guide the development of interventions to maximize
uptake of the HPV vaccine (Ferrer, Audrey, et al., 2015). As such, it was important to
identify the most appropriate framework to guide such development. Although the
constructs of the HBM have been used to explain why mothers are not complying with
the recommendation to vaccinate their daughters against HPV, they have not been used to
consider factors other than maternal-related perceptions that also could influence uptake
of the HPV vaccine series (Ferrer, Audrey, et al., 2015). Similarly, even though the TRA
and TPB have been used to understand the intentions of mothers, adolescent daughters,
and physicians toward discussing HPV-related matters, they have failed to capture factors
other than intention that could influence vaccinating young girls against HPV (Ferrer,
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Audrey, et al., 2015). As established by the SEM, in addition to individual characteristics,
family members, friends, policymakers, and societal and community-level factors are
considered likely to influence uptake of the HPV vaccine (Lanning et al., 2017).
According to Downs et al. (2010), this approach is more likely than approaches that
target only the factors relating to the individuals to enhance uptake of the vaccine series.
Literature Review Related to Key Variables and Concepts
Overview of HPV
Genital HPV is the most common STI in the United States (CDC, 2017). The
infection is so common that for persons who are sexually active, there is a 75% chance
that they will be infected with at least one type of HPV at some point in life (CDC, 2017;
Tota et al., 2011; Valentino & Poronsky, 2016). In the United States alone, approximately
80 million people are infected with HPV, and each year, approximately 14 million newly
infected cases are reported, with nearly 50% of the cases occurring in persons 15 to 24
years of age (CDC, 2017; Tota et al., 2011; Valentino & Poronsky, 2016).
HPV is transmitted through genital contact and is directly transmitted from
infected persons to their sexual partners. Transmission of HPV is not limited to vaginal
intercourse; transmission also can occur during oral and anal sex (Valentino & Poronsky,
2016). Because HPV is transmitted through sexual contact, the risk of infection is linked
to sexual behaviors. Thus, the age when girls begin to engage in sexual activity, have
multiple sexual partners, and not use condoms during sexual intercourse is associated
with a higher risk of being infected with HPV (Chelimo, Wouldes, Cameron, & Elwood,
2013; Valentino & Poronsky, 2016). Likewise, having a history of prior STIs and

31
engaging in nonmonogamous sexual relationships also are associated with a higher risk
of being infected with HPV (Chelimo et al., 2013; Valentino & Poronsky, 2016).
More than 150 strains or serotypes of HPV have been identified, but only about
40 of these serotypes are known to infect humans (CDC, 2017). Even though HPV
infections are common, most infections occur without any symptoms and are cleared by
the immune system within 2 years (CDC, 2017). As a result, most people are not aware
of being infected with HPV and can easily spread the virus to their sexual partners
without knowing it (CDC, 2017). Some infections can persist for years, and if left
untreated, they might progress to cancer (CDC, 2017). Hence, sexually transmitted HPV
serotypes are classified as low risk or high risk based on their cancer-causing potential
(CDC, 2017).
Low-risk HPVs do not cause cancer, but they can cause warts on or around the
genitals and anus (CDC, 2017). HPV Serotypes 6 and 11, for example, are low-risk
serotypes associated with 90% of all genital warts (CDC, 2017). High-risk serotypes can
cause cancer. There are several high-risk serotypes, but HPV Serotypes 16 and 18 are the
most common and are associated with a high percentage of all HPV-related cancers
(CDC, 2017).
HPV-Related Cancers
According to CDC estimates, about 30,000 HPV-related cancers are diagnosed
each year in the United States, with 63% of these cancers affecting women (as cited in
McGhee et al., 2017). Of all HPV-related cancers, 87% of them are cancer of the cervix
(Forman et al., 2012). In the United States, 70% of cervical cancers are HPV related;
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each year, more than 12,820 new cases of cervical cancers are diagnosed, and of these
cases, 4,000 will result in death (ACS, 2017).
Compared to the high rate of HPV-related cervical cancer, the incidence of other
HPV-related cancers remained relatively low for decades. However, in recent years, the
frequency of these cancers has increased (Saslow et al., 2016). Sixty-nine percent of
vulvar cancers, 75% of vaginal cancers, and 70% of oropharyngeal cancers are HPV
related (CDC, 2017; McGhee et al., 2017; Saslow et al., 2016). Each year in the United
States, 1,400 cases of vulvar cancer, 400 cases of vaginal cancers, and 7,000 cases of
oropharyngeal cancers are diagnosed (McGhee et al., 2017).
Before 2006, prevention of cervical cancer was limited to secondary preventative
measures such as screening and early detection with the Pap test (González et al., 2015;
Thomas, 2016). The Pap test is a safe and noninvasive screening tool used to detect
abnormal cells that might lead to cancer if left untreated. However, most women who are
diagnosed with cervical cancer have never been screened for the disease (Glick et al.,
2012; McKeever et al., 2015). In the United States, women from racial and ethnic
minority groups and women from a lower socioeconomic status are 2 to 3 times more
likely to develop cervical cancer because of persistent infection with genital HPV and are
less likely to have had a Pap test (ACS, 2017; Lechuga et al., 2016). For example, even
though Hispanic women tend to have a higher incidence of cervical cancer, they are less
likely than Blacks and other non-Hispanic White women to be screened for HPV-related
cancers (ACS, 2017; Lechuga et al., 2016; Roncancio et al., 2017). Likewise, even
though Blacks have the highest prevalence of HPV infections, they also are less likely to
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be screened for HPV-related cancers (ACS, 2017; Lechuga et al., 2016; Roncancio et al.,
2017).
Cervical cancer is the only HPV-related cancer with guidelines for screening and
a reliable test (CDC, 2016c). Hence, by adhering to screening guidelines, the incidence of
cervical cancer is modifiable (CDC, 2016c). The availability of such guidelines and
reliable tests for oropharyngeal, vaginal, and vulvar HPV-related cancers could help to
reduce the rate (CDC, 2016c), but given the high frequency of these cancers, other
measures should be employed to help to reduce their incidence (CDC, 2017; McGhee et
al., 2017; Saslow et al., 2016). In these situations, a vaccine against HPV would be the
most beneficial. Such a vaccine against HPV would not replace the Pap test or other
screening tools, but it could help to reduce the incidence and mortality rate of HPVrelated cervical cancers. Similarly, a vaccine against HPV could help to reduce the
prevalence of noncervical, HPV-related cancers (Jemal et al., 2013).
HPV Vaccine
Before 2006, there were no vaccines to prevent or reduce the risk of HPV
infection. In 2006, the FDA approved three vaccines against HPV infection (as cited in
FDA, 2018). The first in the series of HPV vaccines to be approved in 2006 was a
bivalent HPV vaccine (2vHPV). This vaccine protects against HPV Serotypes 16 and 18
(Harper & DeMars, 2017). In 2009, the FDA approved a quadrivalent HPV vaccine
(4vHPV). This vaccine targets HPV Serotypes 6, 11, 16 and 18 (Angioli et al., 2016).
Finally, in 2014, a nine-valent vaccine (9vHPV) was introduced to the market. This
vaccine targets HPV Serotypes 6, 11, 16 and 18 as well as 31, 33, 45, 52, and 58 (CDC,
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2017; Draper et al., 2013). All three vaccines were designed to prevent infections with
HPV Serotypes 16 and 18, the most common serotypes causing cancer. In addition,
4vHPV targets HPV Serotypes 6 and 11, both of which are responsible for 90% of genital
warts, and 9vHPV targets five other high-risk HPV serotypes (CDC, 2017).
The HPV vaccine stimulates the immune system to produce antibodies that are
protective against vaccine-related HPV serotypes (Harper & DeMars, 2017).
Comparative analysis of clinical studies supporting the approval of HPV vaccines
indicated that antibodies against 2vHPV and 4vHPV provided protection against 90% to
100% of infection caused by HPV Serotypes 16 and 18 (Einstein et al., 2011a, 2011b;
Einstein, Levin, et al., 2014; Einstein, Takacs, et al., 2014). HPV vaccines also prevent
the formation of precancerous cervical lesions or the transformation of cervical cell
associated with persistent infection with HPV Serotypes 16 and 18 (Einstein et al., 2011a,
2011b; Einstein, Levin, et al., 2014; Einstein, Takacs, et al., 2014). In addition, 2vHPV
and 4vHPV have been found protective against HPV infection in other body sites.
Antibodies against 2vHPV have reduced the number of vulvar HPV infection in young
girls by 50%, and antibodies against 4vHPV have prevented 100% of vulvar and vaginal
lesions caused by HPV infection (Kreimer et al., 2011).
In similar studies, 9vHPV antibodies have been shown to protect against infection
caused by all nine vaccine-related serotypes in all study participants (Joura et al., 2015).
Furthermore, researchers have estimated that by including five additional high-risk
serotypes in the 9vHPV vaccine, the vaccine has the potential to prevent more than 90%
of cervical cancer (De Sanjosé et al., 2010; Joura et al., 2014; Serrano et al., 2012).
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Overall, the HPV vaccines are protective against infections caused by the serotypes of
HPV included in them and they have the potential to reduce the incidence of HPV-related
cancers caused by these serotypes.
A vaccine’s effectiveness is assessed by how efficiently it is taken up by the
population and the level of protection that it subsequently provides through what is called
herd immunity (Kahn et al., 2012). Seven years after the introduction of the HPV
vaccines, Drolet et al. (2015) noted that when vaccine coverage rate exceeded 50%, the
vaccine significantly reduced the prevalence of HPV at the population level. This result
suggested that with higher rates of completion, the prevalence of HPV infection has
become lower, which means more protection for individuals who are unvaccinated
against HPV (Drolet et al., 2015; Harper & DeMars, 2017). The current study supports
not only the importance of being vaccinated against HPV but also the need to improve
the rate of completing the vaccine series within the specified time frame.
Markowitz et al. (2016) provided additional evidence supporting the efficacy of
the vaccine. Using data from the National Health and Nutrition Examination Survey,
these researchers demonstrated that the HPV vaccine significantly reduced the prevalence
of HPV infection among adolescent girls. Because the vaccine was not approved until
late 2006, the researchers used data from 2003 to 2006 to represent the time before the
vaccine and data from 2009 to 2012 to represent the time after the vaccine. Participants
whose HPV status was determined by HPV genotyping were interviewed during each
time frame. The genotyping was included in their analysis.
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Markowitz et al. (2016) found among girls 14 to 19 years of age, the incidence of
HPV infection caused by HPV Serotypes 6, 11, 16 and 18 was reduced by 64%, that is,
from 11.5% prevaccine to 4.3% postvaccination. They also noticed a 34% reduction in
HPV prevalence among participants 20 to 24 years of age. For HPV 16 and 18 alone,
they observed a 50% reduction in infection caused by these two high-risk serotypes. Even
with the low number of participants who completed the three-dose vaccine series, their
results showed that the HPV vaccine was highly effective in preventing HPV infection
and that over time, this reduction in the incidence of vaccine-type HPV serotypes could
reduce cervical cancer and other HPV-related cancers.
In addition to reducing the prevalence of HPV infection, the HPV vaccine series
provides partial protection against other cancer-causing HPV serotypes not included in
the vaccine (Ferris et al., 2014; Petrosky et al., 2015). This information is valuable
because without directly targeting serotypes of HPV not included in the vaccine,
antibodies produced against these strains will be able to offer some protection against
these other strains. Another area of interest in the effectiveness of the HPV vaccines is
the duration of protection, that is, the amount of time (in years) that one is protected
against HPV after receipt of the vaccine. From a clinical perspective, the duration of
protection is critical to preventing HPV infection. For 2vPHV and 4vHPV, after receipt
of all three doses, the duration of protection is currently estimated to be 8 and 9 years,
respectively (Naud et al., 2014). However, because the nine-valent HPV vaccine is
relatively new, its duration of protection is not known. The duration of protection of the
vaccine is important not only to clinicians but also to public health officials because the
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longer the duration of protection, the greater the chances of preventing cervical and other
cancers, such as vaginal, vulvar, and oropharyngeal cancers, that are HPV-related
(Harper & DeMars, 2017; Naud et al., 2014).
One of the objectives of Healthy People 2020 (2018) is to reduce the prevalence
of STIs by promoting healthy sexual behaviors. This goal can be accomplished by
increasing access to services that will help to control STIs and prevent adverse health
outcomes associated with these infections (Healthy People 2020, 2018). For HPV, the
goal is to reduce the proportion of female adolescents who are infected with HPV
(Healthy People 2020, 2018). In the United States alone, 14 million new cases of HPV
are diagnosed each year, with approximately 50% of new cases occurring in persons 15
to 24 years of age (CDC, 2017). Reducing HPV infections is critical not only because
HPV infection is the most common STI but also because HPV is linked to a high
percentage of cervical, vaginal, vulvar, and oropharyngeal cancers in women (CDC,
2017).
Individual and Contextual Factors That Influence HPV Vaccination
Despite the effectiveness of the HPV vaccines, issues relevant to noncompletion
of the series continue. Highlighted in this section are individual and contextual factors
that influence completion of the vaccine series. These factors include age and gender,
race and ethnicity, nativity, socioeconomic status, perceptions about the vaccine, health
care providers’ recommendation, access to health care, and factors relating to Hispanic
individuals.
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Age and Gender
Adolescents should receive the HPV vaccine series before they start engaging in
sexual activity to prevent the spread of HPV and the development of genital warts and
reduce the likelihood of developing HPV-related cancers (CDC, 2017). Currently, the
HPV vaccines are recommended for adolescent girls 11 and 12 years of age, even though
it can be administered to girls as young as 9 years of age (CDC, 2017). For girls and
young female adults 13 to 26 years of age who were not vaccinated or have not
completed the vaccine series within the specified time frame, the CDC (2017)
recommended catch-up vaccines. However, because the vaccine targets young adolescent
girls, the decision to vaccinate is at the discretion of the parents or, in most cases, the
mothers (Fernandez et al., 2010).
Some researchers have found that when compared to girls 13 to 17 years of age,
girls 11 and 12 years of age are less likely to complete the HPV vaccine series (Niccolai
et al., 2011; Reiter, Katz, & Paskett, 2013; Schluterman, Terplan, Lydecker, & Tracy,
2011). Other researchers have not found any association between age and completion of
the HPV vaccine series (Dorell et al., 2011; Verdenius et al., 2013; Widdice et al., 2011).
After controlling for race, insurance, and region of residence, only Cook et al. (2010)
found that older girls 17 years of age were less likely than girls 11 years of age to
complete the HPV vaccine series. In another study, age was not consistently found to be a
factor in completing the HPV vaccine series, but in general, younger girls 9 to 12 years of
age were more likely than adolescents 13 to 17 years of age to comply with a multidose
vaccine (Gallagher et al., 2016). What remains unclear is whether these inconsistent
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findings are associated with the health-seeking behavior of adolescents or whether other
factors are contributing to these differences (Gallagher et al., 2016).
Before 2011, boys were not included in the recommendation to receive the HPV
vaccine; so most of what is known about the factors influencing completion of the HPV
vaccine series has been gathered from studies on preadolescent and adolescent girls.
Since the ACIP expanded its recommendation in 2011 to vaccinate boys routinely against
HPV (Dunne et al., 2011), researchers have consistently demonstrated that boys have
been less likely to initiate and complete the HPV vaccine series, irrespective of age,
insurance status, socioeconomic status, health care usage, and health care center
characteristics (Henry, Swiecki-Sikora, Stroup, Warner, & Kepka, 2018; Kepka, Ding,
Hawkins, Warner, & Boucher, 2016; Moss et al., 2013). Using a national representative
sample of male and female adolescents from the 2014 NIS-Teen, Reagan-Steiner et al.
(2014), showed that of the male adolescents (41.7%) who initiated the vaccine series,
only 21.6% completed it. Comparatively, 60% of the female initiated the vaccine series,
but only 39.7% completed it (Reagan-Steiner et al., 2014). This trend has appeared to be
specific to the HPV vaccine only because the vaccination rate for other adolescent
vaccines has tended to be much higher (Brown et al., 2017; Reagan-Steiner et al., 2014).
Even though the vaccine completion rate has been lower among male adolescents,
completion rates for male and female adolescents remain well below the national
standard of 80%. Hence, although it was not within the scope of this study, increasing the
completion rate of the HPV vaccine series among male adolescents is as much a public
health priority as it is for female adolescents.
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Race and Ethnicity
Race and ethnicity are significant predictors of completion of the HPV vaccine
series among adolescents (Niccolai et al., 2011). Compared to non-Hispanic Whites,
Hispanic, African American, and American Indians adolescent girls have been less likely
to complete the vaccine series (Elam-Evans et al., 2013; McKeever et al., 2015; Wilson,
Brown, Carmody, & Fogarty, 2015). Using a nationally representative sample from the
NIS-Teen, Elam-Evans et al. (2013) showed that HPV vaccine series completion rates for
Hispanic and African American adolescents were consistently low during the 2010-2013
cycle. For female adolescents who initiated the vaccine series in 2013, Hispanics and
African Americans were less likely than White girls of similar age to complete the series
(Elam-Evans et al., 2013).
Moreover, these rates have tended to vary from state to state. States with a high
percentage of adolescent girls from racial and ethnic minorities have tended to have
lower completion rates (McKeever et al. 2015). For example, Mississippi has been found
to have the lowest completion rate (19%) when compared to a 57.7% completion rate for
Rhode Island (Dunne et al., 2014; Elam-Evans et al., 2013). Together, these findings
suggest that there is either limited access to preventive services or underutilization of
these services, even if they are accessible.
Country of Birth
According to the U.S. Census Bureau (2013), 4.1% of individuals 10 to 14 years
of age and 7% of individuals 15 to 19 years of age living in the United States were born
in other countries. Vaccination practices, access, availability, and schedules in other
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countries might be different from those in the United States; therefore, vaccine coverage
among foreign-born persons might be below U.S. national standards (Healy et al., 2018).
Based on the literature, the country of birth can negatively affect vaccination coverage
among young children (Varan et al., 2017) and adults (De & Budhwani, 2017; Lu,
Rodriguez-Lainz, O’Halloran, Greby, & Williams, 2014; Pérez, Agénor, Gamarel, &
Operario, 2018). For example, compared to U.S.-born infants less than 12 months of age,
foreign-born infants have lower odds of being up to date on the routinely recommended
vaccines for this age group (Varan et al., 2017). Likewise, compared to U.S.-born
children 19 to 35 months of age, foreign-born children of similar ages are less likely to
complete the combined vaccine series recommended for this group (Varan et al., 2017).
The same trend also has been observed for adults, whereby foreign-born adults, compared
to adults born in the United States, 18 to 32 years of age are less likely to initiate and
complete the HPV vaccine series (De & Budhwani, 2017; Pérez et al., 2018).
Until recently, not much was known about the relationship between country of
birth and vaccine coverage among adolescents. Unlike young children and adults, the
results of a study by Healy et al. (2018) did not find any association between country of
birth and coverage rate for the vaccines recommended for this group. Using data from the
2012-2014 NIS-Teen, Healey et al. found that coverage rates for the measles, mumps,
and rubella vaccine (MMR); acellular pertussis vaccine; and meningococcal conjugate
vaccine were comparable for foreign-born and American-born adolescents 13 to 17 years
of age. Although foreign-born adolescents had a slightly lower coverage rate for hepatitis
B vaccine, the coverage rate for hepatitis B was high for both groups (Healy et al., 2018).
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However, for HPV and varicella, the vaccination coverage rate was low for both groups
(Healy et al., 2018).
Among foreign-born girls, Healy et al. (2018) found that the unadjusted coverage
rate for all doses of the HPV vaccine series was less than 38%; however, after adjusting
for access to health care, socioeconomic factors, and demographic factors, such disparity
no longer existed. This finding suggests that even though vaccine coverage rates are
comparable for American-born and foreign-born adolescents, vaccination disparities still
exist among this cohort. As highlighted in the Healy et al. study, socioeconomic and
demographic disparities, as well as disparities in health care access, affect vaccine
uptake, and as seen in this study, they do account for some of the differences seen in
vaccine coverage among adolescents.
Perceptions of the HPV Vaccine
Maternal-Related Factors
Mothers’ perceptions of the HPV vaccine are very influential to its uptake
(Morales-Campos & Parra-Medina, 2017). For some mothers, it has been easier for them
to justify accepting the vaccine because it prevents cancer (Morales-Campos & ParraMedina, 2017; Roncancio et al., 2016, 2017). Some mothers have tended to believe that
the vaccine is not necessary and that their daughters are too young to get the vaccine
(Bastani et al., 2011; Laz et al., 2012). Other mothers have perceived that using the
vaccine would promote sexual activity at a young age or promote high-risk sexual
practices (Hendry, Lewis, Clements, Damery, & Wilkinson, 2013). However, based on
the results of several studies, HPV vaccination is not associated with riskier sexual
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behavior (Bednarczyk, Davis, Ault, Orenstein, & Omer, 2012; Liddon, Leichliter, &
Markowitz, 2012; Mayhew et al., 2014).
The HPV vaccines are relatively new. Since their introduction, mothers have
continuously voiced their concern about the safety of the vaccines (Berenson, 2015).
These concerns have revolved around the side effects of the vaccines and any possible
adverse effects that could affect the overall health and fertility of girls (Berenson, 2015;
Schuler, Hanley, & Coyne-Beasley, 2014). Despite concerns about the safety of the
vaccines, the vaccination of adolescent Hispanic girls is likely if the mothers believe that
the vaccine prevents HPV infection and cervical cancer (Gold, Naleway, & Riedlinger,
2013; Roncancio et al., 2016). Based on perceived barriers and facilitators to getting the
HPV vaccines, Hispanic mothers may or may not vaccinate their daughters against HPV
(Roncancio et al., 2016). For example, availability of transportation, the ease of making
appointments, and the ability to discuss the matter with health care providers can impact
the chances of completing the vaccine series (Roncancio et al., 2016, 2017).
Maternal acceptability of the vaccine is one of the strongest predictors of
adolescents not only accepting the vaccine but also actually getting the vaccine
(Roncancio et al., 2016, 2017). Acceptability of the HPV vaccines is associated with
maternal knowledge and awareness of HPV, HPV-related cancers, and the HPV vaccines
(Morales-Campos & Parra-Medina, 2017). Several researchers have cited maternal lack
of knowledge about HPV, the vaccine, and HPV-related outcomes as a barrier to
vaccination (Dorell et al., 2011; Laz et al., 2012; Stokely et al., 2014). Likewise, although
receipt of a recommendation from health care providers regarding HPV vaccination is
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influential, some mothers view the lack of such recommendations as a sign that the
vaccine must not be important (Laz et al., 2012; Stokely et al., 2014). Hence, without
additional information about the vaccines and a recommendation from health care
providers, adolescents are less likely to complete the vaccine series (Laz et al., 2012;
Stokely et al., 2014).
Risk of HPV infection also has been cited as a barrier to vaccine uptake. Mothers
who perceive that their children are not at risk of HPV infection or HPV-related cancers
are less likely to have them vaccinated against the disease (Bastani et al., 2011; Laz et al.,
2012). Conversely, Markovitz, Song, Paustian, and Reda (2014) found that mothers’ use
of preventive services like the Pap test is more predictive of their daughters receiving the
HPV vaccines. This finding implies that mothers who are aware of HPV and HPV-related
cancers and who themselves have taken steps to prevent cervical cancer can positively
affect the HPV vaccination status of their daughters.
Adolescent Perceptions About the Vaccine
Most adolescents have a basic knowledge or understanding of HPV infection and
the HPV vaccines (Valentino & Poronsky, 2016). However, depending on where they get
their information, they might be misinformed about HPV infection and the vaccines
(Berenson, 2015). One study in Texas by Morales-Campos et al. (2013) found that among
girls 14 to 17 years of age, many did not know about cervical cancer, what caused it, how
it could be prevented, or who was at risk of developing it. For adolescents who are
misinformed, what they know about HPV and the vaccines can negatively affect their
overall attitude toward them (Forster, Marlow, Wardle, Stephenson, & Waller, 2010;
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Rambout, Tashkandi, Hopkins, & Tricco, 2014). Some adolescents believe that the
vaccines are neither necessary nor effective (Forster et al., 2010; Rambout et al., 2014).
Still, others believe that because they are not sexually active, are married, or are in
monogamous relationships, the vaccine is not needed (Liddon et al., 2012: Zimet, Weiss,
Rosenthal, Good, & Vichnin, 2010).
When adolescent girls value the opinions of their mothers, they are more likely to
mirror the attitudes and opinions of their mothers (Mullins et al., 2013). In such cases, if
the mothers do not agree with the HPV vaccine, the daughters also are less likely to
comply with the three-dose vaccine regiment (Mullins et al., 2013). Adolescents are,
however, more likely to complete the vaccine series if they perceive that they are at risk
of HPV infection and cancer and are susceptible to STIs (Kessels et al., 2012). They are
also more likely to complete the vaccine series if they perceive HPV as severe and
believe that the vaccine is protective against HPV or can prevent cancer (MoralesCampos et al., 2013).
Provider Recommendation
Of the factors most often associated with the uptake of the HPV vaccine series,
receipt of a recommendation from health care providers is the strongest predictor of being
vaccinated against HPV (Brewer et al., 2011; Gilkey et al., 2015, 2016; Holman et al.,
2014; Lau, Lin, & Flores, 2012; Reiter, McRee et al., 2013). Receipt of a
recommendation from health care providers to vaccinate against HPV is so instrumental
that 70% of the recipients of such a recommendation have initiated the vaccine series
(Dorell et al., 2010). Using a national online survey, Gilkey et al. (2016) found that 75%
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of the study participants who received a recommendation from their health care providers
initiated the vaccine series and about 43% of them completed the vaccine series.
Despite the impact of health care providers’ recommendation regarding uptake of
the HPV vaccine, not all adolescent girls receive a recommendation from their health care
providers (Gilkey et al., 2015, 2016). Girls from racial and ethnic minorities, particularly
Hispanic and African American girls, are less likely to receive a recommendation to get
the HPV vaccine from their health care providers (Morales-Campos et al., 2013). Girls
living below the federal poverty level are also less likely to receive such a
recommendation (Niccolai et al., 2011). If they have received a recommendation from
their health care providers, analysis of data from the NIS-Teen 2009 survey showed that
Hispanics and African Americans were as likely as their White age mates to get the
vaccine (Ylitalo, Lee, & Mehta, 2013).
Among African American and Hispanic adolescents, the lack of a
recommendation from health care providers to get the HPV vaccine might be associated
with not having regular medical homes, being uninsured, and using preventive care
services irregularly, even if they are accessible (Holman et al., 2014). The lack of a
recommendation by health care providers among ethnic minorities might be exacerbated
by factors inherent to their status as immigrants (if applicable); among these factors are
low health literacy, language barriers, low levels of acculturation, and so on (Jeudin et al.,
2014). Gerend et al. (2013) found that the odds of receiving a recommendation to get the
HPV vaccine series were higher among individuals who were more acculturated than
among individuals who were less acculturated.
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Although the emphasis of health care providers’ recommendation is reflected
more in the percentage of persons who start the HPV vaccine series, such a
recommendation is equally important to complete the HPV vaccine series (Kepka et al.,
2015). Health care providers also should stress the importance of completing the vaccine
series to be protected fully against HPV (Berenson, 2015). The providers should inform
parents and adolescents that they have to return for the second and third doses (Berenson,
2015). This oversight was made evident by a study that evaluated the HPV knowledge of
Hispanics in Utah (Kepka, Ulrich, & Coronado, 2012). The results of this study revealed
that among the survey participants, most parents were not aware that the HPV vaccine is
a multidose vaccine (Kepka, Ulrich, & Coronado, 2012). By highlighting the importance
of initiating as well as completing the vaccine series, health care providers can drastically
boost the level of HPV vaccine completion among adolescents, especially among
adolescent girls from racial and ethnic minority groups.
Financial Barriers
Cost of the Vaccine
The HPV vaccine is one of the most expensive vaccines to date. In U.S. dollars,
the cost per dose, if using the 4vHPV, ranges from $121 to $160 (CDC, 2015b). If the
9vHPV is received, the cost ranges from $168 to $204 per dose (CDC, 2018). In total,
completing either the 4vHPV or the 9vHPV series can cost from $363 to $480 or $504 to
$612, respectively (CDC, 2015b, 2018). The difference in price is based on whether the
vaccine is covered or not covered by public or private insurance. The lower prices are for
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Medicaid or Vaccination for Children (VFC) recipients, and the higher prices are for
those with private insurance or who are paying out of pocket (CDC, 2018).
For parents, the cost of the vaccine can be burdensome. Not every adolescent is
eligible for Medicaid, and not everyone can afford private insurance or pay for the
vaccine out of pocket (Bruno, Wilson, Gany, & Aragones, 2014; Warner et al., 2015).
Likewise, not everyone qualifies for the VFC program, which provides the vaccine at no
cost to eligible recipients (CDC, 2016d). Furthermore, even if the children qualify for
VFC, some parents might not know about this program (Reiter, Katz, & Paskett, 2013).
Persons without insurance coverage might struggle to pay the high cost of the vaccine or
might even choose not to get it because they might view it as a nonurgent medical matter
(Nordin, Solberg, & Parker, 2010).
Health Care Providers’ Administrative Fees
From the perspective of health care providers, it is difficult for doctors to store
and administer the vaccine to their patients (Quinn, Murphy, Malo, Christie, &
Vadaparampil, 2012). In their private practices, doctors pay for and stock the vaccine so
that it is readily available to administer to patients. In addition to paying for the vaccines
themselves, doctors absorb the cost of storing and administering the vaccine. Although
they keep the vaccine in stock as a service to their patients, they stand to lose or gain very
little from doing so because they are reimbursed poorly for this service (Gable, Eder,
Noonan, & Feemser, 2016). Without incentives, health care providers might be less
inclined to offer such services or recommend the vaccine to persons who are either
underinsured or uninsured (Pourat & Jones, 2012; Ylitalo et al., 2013). Because girls

49
from racial and ethnic minority groups are more likely to be underinsured or uninsured,
they are less likely to receive a recommendation for the HPV vaccination from their
health care providers.
Socioeconomic Status
Low socioeconomic status, that is, lower disposable income and lower education,
highly correlates with the incidence of cervical cancer in the United States (González et
al., 2015). However, relative to the HPV vaccine, very few studies in the United States
have captured the ways that socioeconomic factors affect the uptake of the vaccine series
among adolescent girls. Results of these few studies have either been insignificant or
conflicting, indicating that HPV vaccination uptake was less likely among individuals
living below the poverty level (Fisher, Trotter, Audrey, MacDonald-Wallis, & Hickman,
2013; Roberts et al., 2010) or was not associated with low income (Pruitt & Schootman,
2010).
Family income. Polonijo and Carpiano (2013) analyzed data from the 2008-2010
NIS-Teen to assess social inequalities associated with vaccinating adolescents against
HPV. Based on their analysis, yearly estimates of household income from 2008 to 2010
were inconsistently associated with completion of the vaccine series. Likewise, the odds
of completing the vaccine series were significantly lower (23%-25%) for girls from lowand middle-income households than for girls from higher-income households (Polonijo &
Carpiano, 2013). However, multivariate analyses from other studies showed that parental
income (Gold et al., 2013; Laz et al., 2010); neighborhood income; and household
income (Markowitz et al., 2014) were not associated with completion of the HPV vaccine
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series.
Results of a study conducted in Denmark by Slåttelid Schreiber, Juul,
Dehlendorff, and Kjaer (2015) showed that despite having free access to the HPV
vaccine, adolescent girls from ethnic minority groups were less likely to initiate and
complete the vaccine series. Compared to Danish adolescent girls from households with
parents having more disposable income, adolescent girls whose parents had less
disposable income were less likely to initiate and complete the vaccine series (Slåttelid
Schreiber et al., 2015). Likewise, compared to Danish girls whose mothers were married
and employed, girls whose mothers were unmarried and unemployed tended to have
lower odds of initiating and completing the vaccine series (Slåttelid Schreiber et al.,
2015).
Another study conducted in Norway (B. T. Hansen, Campbell, Burger, & Nygard,
2015) did not find an association between socioeconomic factors and completion of the
vaccine series. In this study, B. T. Hansen et al. (2015) noted that initiation of the vaccine
series correlated with parental ages and incomes, receipt of the MMR vaccine, and
maternal occupations. However, only receipt of the MMR vaccine correlated with
completing the HPV vaccine series; socioeconomic factors did not have any effect on
completion rate (B. T. Hansen et al., 2015). If the girls did not receive the MMR vaccine,
their chances of completing the HPV vaccine series was considerably lower than if they
had been vaccinated (B. T. Hansen et al., 2015).
Maternal education. Polonijo and Carpiano (2013) identified an association
between maternal education and completion of the vaccine series varies. They concluded
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that as the level of maternal education decreased, the odds of completing the HPV
vaccine series were 11% to 28% lower for uneducated versus college-educated mothers.
Multivariate analyses from another study showed that the level of parental education was
not associated with completion of the HPV vaccine series (Fisher et al., 2013).
The study conducted by Slåttelid Schreiber et al. (2015) showed that despite
having free access to the HPV vaccine, adolescent girls from ethnic minorities were less
likely to initiate and complete the vaccine series. Compared to Danish adolescent girls
from households with parents having higher levels of education, adolescent girls whose
parents were less educated were less likely to initiate and complete the vaccine series
(Slåttelid Schreiber et al., 2015). However, B. T. Hansen et al. (2015) did not find any
association between education and completion of the HPV vaccine series. B. T. Hansen et
al. concluded that even though initiation of the vaccine series correlated with parents’
educational attainment, receipt of the MMR vaccine, and maternal occupation, only
receipt of the MMR vaccine correlated with completing the HPV vaccine series. Thus,
they argued that socioeconomic factors did not have any effect on completion of the
vaccine series. It was more likely that if the girls did not receive the MMR vaccine, they
were less likely to complete the HPV vaccine series (B. T. Hansen et al., 2015).
Hispanics and the Risk of HPV
Hispanic Health
Hispanics are the fastest growing and the largest ethnic group in the United States.
Currently, the Hispanic population accounts for 17.6% (56.5 million) of the U.S.
population and comprises Mexicans (66%), individuals from South and Central America
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(13%), Puerto Ricans (9.5%), Cubans (4%), and other Hispanics (7.5%; Pew Research
Center, 2017; U.S. Census Bureau, 2013). Hispanics under the age of 18 years account
for approximately 17% of the U.S. population of children, and this percentage is expected
to increase to 28.6% by 2060 (Colby & Ortman, 2014).
Hispanics are an exceptional class of immigrants. Although they are
disadvantaged socioeconomically, their overall health is better than that of African
Americans and non-Hispanic Whites (Camacho-Rivera, Kawachi, Bennett, &
Subramanian, 2015). This health advantage has been associated with some sociocultural
factors that are protective against unhealthy behaviors (Lam, Goldenson, Burner, &
Unger, 2016). These factors include family, religion, and cultural or traditional beliefs
and practices that promote certain behaviors that are not destructive to one’s overall wellbeing (Johnson-Motoyama, 2014; Lam et al., 2016). However, the longer that Hispanic
individuals reside in the United States, the more they are exposed to behaviors that
ultimately cause them to lose their health advantage (Camacho-Rivera et al., 2015; Ro,
2014).
Deterioration in the health of Hispanics has been partially attributed to social and
structural factors that shape the conditions in which they live (Velasco-Mondragon et al.,
2016). Among these factors are lower levels of education, lack of access to health care
services, lower socioeconomic status, underinsured or uninsured status, and low-paying
jobs (Velasco-Mondragon et al., 2016). These challenges are further compounded by
federal and state policies and practices that restrict their access to health services and
social programs (Johnson-Motoyama, 2014). It has been estimated that more than 80% of
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Hispanic children (i.e., < 18 years of age) born in the United States are the children of
unauthorized immigrant parents (Passel & Cohn, 2011). As U.S. citizens, these children
would naturally qualify for most programs, but because of laws and policies that affect
their parents negatively, they cannot participate in such programs (Johnson-Motoyama,
2014; Seiber, 2013). This fact is important to note because it offers some explanation for
the high percentage of Hispanic children and adolescents who are underinsured or
uninsured and why they access preventive care services sporadically, if at all (Schmeer,
2012).
HPV Among Hispanics
In the United States, Hispanic women have the highest incidence of cervical
cancer (ACS, 2017; Kepka et al., 2015). They are 2 to 3 times more likely to develop
cervical cancer because of persistent infection with genital HPV and are less likely to
have had a Pap test (ACS, 2017; Lechuga et al., 2016). Compared to non-Hispanic White
women, the incidence of cervical cancer among Hispanic women is 74% higher, and the
mortality rate among this group of women is 48% higher (ACS, 2017). Each year,
approximately 2,000 Hispanic women are diagnosed with cervical cancer, and
approximately 600 of them die from the disease (ACS, 2017). Given the incidence of
cervical cancer among Hispanic women, HPV vaccination might be of great importance
to this group of women. Researchers have shown that even though Hispanic adolescent
girls are more likely to initiate the HPV vaccine series, they are less likely than nonHispanic White adolescent girls to complete the three-dose series (Jemal et al., 2013;
Niccolai et al., 2011; Polonijo & Carpiano, 2013). Over time, if this pattern of vaccine
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coverage persists among Hispanic girls, the gap in HPV-related disparities for this group
of women is likely to widen (Roncancio et al., 2017).
Acculturation, Health Literacy, Social Influence, and HPV Vaccination
Relative to Hispanics and the reduction of their risk of HPV infection,
acculturation might not only be a barrier but also a facilitator of their being vaccinated
(Gerend et al., 2013; Held & Cuellar, 2016; Kepka et al., 2015). Acculturation refers to a
sociocultural process through which individuals from a cultural group adapt to the culture
of the host country as a result of exposure to its values, beliefs, attitudes, behaviors, and
customs (Lopez-Class, Castro, & Ramirez, 2011; Ward & Geeraert, 2016). Individuals
vary in their level of acculturation, and based on their level of acculturation, they might
or might not be at a disadvantage for poor health outcome (Lopez-Class et al., 2011;
Ward & Geeraert, 2016). For example, individuals who are more acculturated are more
likely than individuals who are less acculturated to receive a recommendation for HPV
vaccination from their physicians (Gerend et al., 2013). Conversely, a high level of
acculturation is associated with adopting behaviors such as engaging in risky sexual
practices that increase the risk of HPV, as suggested by Kepka, Coronado, Rodriguez,
and Thompson (2010). Analysis of data from the 2003-2004 National Health and
Nutrition Examination Survey indicated that Mexican American women who were more
acculturated than women who were less acculturated were more likely to be infected with
high-risk HPV serotypes (Kepka et al., 2010).
Although researchers have contended that acculturation has a positive effect on
disease prevention (Breen, Rao, & Meissner, 2010; Lebrun, 2012), how it correlates with
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completing the HPV vaccine series remains unclear. Some researchers have reported not
finding an association between acculturation and initiation of or intention to initiate the
HPV vaccine series (Guerry et al., 2011; Luque et al., 2010). In other studies,
acculturation has been reported as a barrier to the uptake of the HPV vaccine (Walter et
al., 2017) and that acculturation has contributed to the racial and ethnic disparities
associated with the uptake of the HPV vaccine (Wisk et al., 2014). However, Gerend et
al. (2013) found that acculturation was associated with the uptake of the HPV vaccine,
meaning that more acculturated mothers were more likely than mothers who were less
acculturated to have their children vaccinated against HPV.
Individuals who are less acculturated tend to have limited health literacy, which
impedes their ability to make health-related decisions and to follow certain health-related
directives (Ciampa et al., 2012). As such, Hispanics or Spanish speakers are at a higher
risk of experiencing problems related to health literacy (R. Singh, Coyne, & Wallace,
2015). Besides having variations in HPV-related knowledge, having limited health
literacy also might prevent Hispanics from accessing better HPV-related information and
then processing such information to help them to make more informed decisions about
receiving the vaccine (Baldwin, Bruce, & Tiro, 2013). HPV literacy among Hispanic
mothers is associated with a higher chance of their daughters being vaccinated against
HPV, thus reducing the children’s risk of infection (Beltran, Simms, Lee, & Kwon, 2015;
Wisk et al., 2014). Hispanic mothers with low literacy have lower odds of vaccinating
their daughters against HPV, thus increasing their daughters’ risk of HPV infection
(Beltran et al., 2015; Wisk et al., 2014). The same is true of mothers who are unaware of
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or have limited knowledge of HPV, the vaccine, and HPV-related diseases (Beltran et al.,
2015; Wisk et al., 2014).
The literature has shown that immigration disrupts the social networks of
Hispanic immigrants. Compared to U.S.-born Hispanics, foreign-born Hispanics tend to
have lower social support, meaning that they will have fewer sources at their disposal to
assist them in making health-related decisions (Allen et al., 2014). For Hispanics, the
family is highly valued and is integral to the decision-making process. The nursing
theory-health promotion model posits that people are more likely to obtain health
information from peers, friends, and family members, and are subsequently more likely
to engage in health behaviors that positively affect their health when people in the social
circle model the behaviors and show their support to enable the behaviors (Nursing
Theory, 2016). Therefore, for immigrants who are socially connected, having other
people who model or support certain health-related behaviors (e.g., vaccinating against
HPV) reflects the likelihood of engaging in such behaviors. If they know someone who
has completed the vaccine series or has cervical cancer, Hispanic mothers are more likely
to vaccinate their daughters against HPV (Morales-Campos et al., 2013; Stephens, Tamir,
& Thomas, 2016). Likewise, adolescent girls are more likely to get the vaccine if they
know that their friend(s) have gotten the vaccine. Likewise, the negative experiences of
others, their negative attitudes toward health care providers, and the type of information
relayed about HPV and the HPV vaccine can adversely affect the decision to be
vaccinated (Stockwell, Irigoyen, Martinez, & Findley, 2011).
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Because newly immigrated Hispanic mothers might not have the resources (e.g.,
health insurance or access to health information) to maintain the health of their families,
it is important for them to be socially connected (W. Kim, Kreps, & Shin, 2015). Being
acculturated and socially connected are important because interacting with others will
serve as a source of information (e.g., affordable services, the location of clinics, etc.). In
addition, by interacting with other mothers, they will learn about the health-related norms
of the host country (W. Kim et al., 2015). Mothers who associate with others who have
accepted the HPV vaccine are more likely to ensure that their children receive the vaccine
as recommended. For mothers who are unacculturated or who are not health literate,
people in their social networks can be a source of information, and they can help the
mothers to find the necessary information and resources (Y. C. Kim, Lim, & Parks,
2015).
Access to Health Care and HPV Vaccination
Receiving a health care provider recommendation for HPV vaccination and
having regular preventive care visits are critical to the uptake of the HPV vaccines.
Adolescent girls from racial and ethnic minority groups and girls from families with
lower socioeconomic status are more susceptible to having limited access to preventive
care services and receiving poorer quality of care (Gelman et al., 2013; Polonijo &
Carpiano, 2013). Hispanics are distinctly at a disadvantage in terms of receiving quality
and appropriate care to meet their needs. Whether seeking to address medical issues or
use preventive services, Hispanics in the United States have limited access to health
services and are less likely to have primary medical homes. They also are less likely than
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other racial and ethnic groups to use preventive care services (Gelman et al., 2013;
Velasco-Mondragon et al., 2016). Because health care providers are needed to administer
the vaccine, adolescents from racial/ethnic minority groups who have limited or no
access to preventive care services will continue to be underimmunized (Gelman et al.,
2013).
Even if their primary health care providers are accessible, many U.S. adolescents
do not see them for the recommended annual well-care visit (Bruno et al., 2014). Based
on a survey of physicians servicing racial/ethnic minority communities, about 70% of
these doctors reported that a limiting factor for receiving a recommendation for the HPV
vaccine was the lack of preventive care visits by eligible adolescents (Bruno et al., 2014).
Even with insurance coverage, Tsai, Zhou, Wortley, Shefer, and Stokley (2014)
commented that among adolescents who are privately insured, approximately 43% of
them had made at least one preventive care visit at the time of the study. Relative to the
HPV vaccine, this fact is concerning because preventive care visits are the ideal situations
for health care providers to recommend and administer the vaccine (Berenson, 2015).
Dorell et al. (2011) reported that after controlling for sources of information and
health care utilization, adolescent girls and young adult females were more likely to
receive the HPV vaccine series if they had made recent health care visits and had
discussed getting vaccinated with their health care providers. Preventive care usage also
varies by U.S. state (Moss, Reiter, & Brewer, 2015). For girls living in states with high
percentages of preventive care service usage, Moss et al. (2015) found that the likelihood
of completing the HPV vaccine series was higher among these girls than among girls
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living in states with lower percentages of preventive care usage. These findings suggest
that interactions with health care providers and residence in areas where the use of
preventive care services is high influence the likelihood of being vaccinated.
Having primary medical homes is crucial. Test, Caskey, and Rankin (2013)
evaluated the relationship between receiving the HPV vaccine series and having
permanent medical homes. They concluded that girls with permanent medical homes
were more likely than girls without permanent medical homes to get the vaccine. This
finding suggests that having permanent medical homes is influential in the uptake of the
vaccine. In another study (Perreira et al., 2012), Hispanics were found to be less likely to
have permanent medical homes and turned, instead, to hospitals, community health
centers, public clinics, or school-based health centers to meet their health care needs. By
using these different facilities, some parents might not recognize the need to establish
permanent medical homes (Banspach et al., 2016; Nordin et al., 2010).
From a public health perspective, these facilities are attractive because they can
serve as points of contact to help in delivering the HPV vaccine to ensure that girls can
either initiate or complete the vaccine series (Guleria, Jones, Zimmerman, Stempinski, &
Patel, 2016). Besides being points of care for delivering the vaccine, these sites have the
potential to help to address such issues as differences in language and literacy levels that
impact the patient-provider relationship (Javier, Festa, Florendo, & Mendoza, 2015).
They also might help to address barriers specific to the health care system, such as
geographic availability and staff competency (Javier et al., 2015). Using different facility
types to obtain health care services does not eliminate the need to establish primary
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medical homes, but they do have the potential to help to reduce disparities in access to
health care services. The role that they play in delivering the HPV vaccine might also
offer further insight into differences seen in the uptake of the HPV vaccine among
adolescents.
Insurance Coverage and HPV Vaccination
The most cited reasons for not accessing health care services are either the lack of
health insurance or inadequate insurance (G. K. Singh et al., 2013). The HPV vaccine
series is costly (Lu et al., 2018), so without coverage by private insurance or Medicaid, it
might be a struggle for some parents to pay for it out of pocket. Children of immigrant
parents have lower health insurance coverage than children of U.S.-citizens (Jarlenski et
al., 2016). Compared to other racial and ethnic minority groups, Hispanics tend to have
the highest percentage of uninsured children and adolescents (Berdahl, Friedman,
McCormick, & Simpson, 2013; G. K. Singh et al., 2013). Likewise, most people living
below the poverty level are either African American or Hispanic, so from this
perspective, African Americans also are likely to have a high percentage of uninsured
children (Jeudin et al., 2014).
Being underinsured or uninsured does affect the likelihood of being vaccinated
against HPV. In general, researchers have determined that private insurance holders have
higher odds of completing the vaccine series than individuals who are either uninsured or
are covered by public insurance (Dorrell et al., 2011; Harper et al., 2014; Widdice et al.,
2011). Researchers analyzing data from the NIS-Teen have found that vaccine initiation
and completion were the lowest among adolescent girls who were not insured (Reiter,
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Katz, et al., 2013; Reiter et al., 2014). What was striking about this finding is that these
girls qualified for free vaccines under the VFC Program, but whether they even knew
about the program or their eligibility was unclear (Reiter et al., 2014).
Eligibility and free HPV vaccination do not necessarily mean that the rate of
completing the vaccine series will increase (Harper et al., 2014). In a retrospective cohort
study, Harper et al. (2014) found that providing the HPV vaccine at no cost did not
significantly influence completion of the vaccine series; in fact, none of the recipients of
the free vaccine completed the series. This finding suggests that other factors might have
been contributing to this outcome.
Whether privately or publicly insured, continuity in coverage or maintenance of
coverage is critical to receipt of the vaccine (Rand & Goldstein, 2018). Based on the
literature, insurance coverage is normally assessed at a single point in time, usually at the
time of the medical visit or when the survey is administered. However, in doing so,
researchers have failed to capture periods when persons were uninsured resulting from
discontinuity in coverage (Cowburn et al., 2014; DeVoe et al., 2015). For vaccines that
are administered in a single does, discontinuity or gaps in insurance coverage might not
be as worrisome, but for multidose vaccines like the HPV vaccine series, this gap can be
problematic (Cowburn et al., 2014). As recommended, the HPV vaccine is administered
over 6 months, that is, at baseline (0 months), 2 months, and 6 months. However, not
everyone adheres to this schedule, so some individuals might need more than 6 months to
complete the series. During this time, insurance coverage status might change, thus
affecting the likelihood of completing the vaccine series (Cowburn et al., 2014). When
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insurance status is measured at a single point in time, it is difficult to assess the ways that
discontinuity in coverage might influence the uptake of multidose vaccines like the HPV
vaccine series (Cowburn et al., 2014).
Discontinuity in insurance coverage or gaps in insurance coverage might be as
problematic as being uninsured. Discontinuity in coverage has been associated with
limited or inconsistent use of preventive services, unmet medical needs, and the inability
to fill prescriptions (DeVoe et al., 2015; Guevara et al., 2014; Wisk & Witt, 2012). Based
on the literature, being Hispanic adolescents 10 to 18 years of age from families with
incomes below the federal poverty level predicts whether or not the children are likely to
experience gaps in insurance coverage (DeVoe et al., 2015; Fairbrother et al., 2011).
Similarly, being adolescents in families where only one parent is employed also predicts
whether the children are continuously insured, or not (DeVoe et al., 2015). For employerprovided insurance, the parents might not be able to afford family coverage, so the
children of these parents might not have any coverage for an extended period (DeVoe et
al., 2011). Similarly, for individuals who rely on employer-provided health insurance,
changes in parental employment status can lead to changes in coverage or even the loss
of coverage (Smits-Seemann et al., 2016).
Regarding vaccinations, being insured continuously should not matter for children
less than 18 years of age. This is because children who are uninsured, underinsured, or
eligible for Medicaid can still get vaccines at no cost through the VFC Program (CDC,
2016d). However, DeVoe et al. (2015) and Yamauchi, Carlson, Wright, Angier, and
DeVoe (2013) noted that parental insurance status does affect the insurance status of the
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children, that is, continued parental coverage increases the likelihood of the children
maintaining coverage. This finding suggests that disrupting parental insurance coverage,
whether private or public, is likely to affect the children’s coverage.
Cowburn et al. (2014) specifically looked at insurance continuity and HPV
vaccine uptake in two states and found that for adolescents 13 to 17 years of age,
insurance continuity did matter. Analysis of data from federally qualified health centers
in the two states showed that adolescents 13 to 17 years of age were significantly less
likely to initiate the HPV vaccine series if they were not insured continuously. However,
in their study, Cowburn et al. stated that insurance coverage did not significantly predict
the likelihood of completing the vaccine series. One shortcoming of the study was that
Cowburn et al. were limited to using electronic health records specific to these centers,
meaning that they could not assess how the data compared to the data of existing vaccine
registries.
It also was possible that different categories of insurance coverage affected uptake
of the HPV vaccine series or that the disruption in insurance coverage or no coverage at
all was underestimated by Cowburn et al. (2014). Taken together, disparities in vaccine
relative to insurance status could have been attributed to the underreporting of
vaccination status, thus limiting the findings of their study. Overall, gaps in insurance
coverage are not uncommon and should be taken into consideration when assessing
insurance coverage and the completion of multidose vaccines.
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Summary
Completing the HPV vaccine series is important to all adolescents. However, it is
more important for Hispanic adolescent girls to complete the series, given that Hispanic
women have the highest incidence of cervical cancer. Despite the availability and
effectiveness of the HPV vaccine, completion of the series remains low among
adolescent Hispanic girls. Although Hispanic adolescent girls are more likely than nonHispanic White girls to initiate the vaccine series, they are less likely to complete it for a
variety of reasons, including having limited access to health care and being underinsured
or uninsured. Because Hispanic adolescents are less likely to have permanent medical
homes, they also are less likely to have at least one annual well-care visit, and they are
more likely to have their health care needs met at other facilities, making it unlikely that
they will receive the vaccine during these visits. To maximize uptake of the HPV vaccine
series, it should be offered at all visits, irrespective of where the visits occur.
Similarly, insurance status also can impact access to the vaccine. To be specific,
continuity in insurance coverage is crucial to adolescent health. For adolescents,
obtaining and maintaining health insurance coverage is determined by their parents’
insurance status. Parental insurance coverage decreases the likelihood of gaps in
insurance coverage for the children. Being insured continuously means sustained access
to preventive services and stability of care (i.e., multiple visits to complete the vaccine
series).
Despite evidence supporting the effectiveness of the HPV vaccine series, the
limited uptake of the vaccine among the high-risk population remains a concern. To
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address disparities in HPV vaccine coverage and HPV-related disparities among Hispanic
women, efforts to increase uptake of the HPV vaccine series among this population are
needed. Guided by this review of the literature, the current study helped to fill a gap in
the literature by assessing the ways that the source of health care and continuity in
insurance coverage influenced completion of the HPV vaccine series among Hispanic
girls. Analyzing the role of different sources of health care on the uptake of the HPV
vaccine helped to clarify whether using the facilities in question would facilitate greater
uptake of the vaccine among Hispanic adolescents. To address issues regarding health
insurance coverage, it was important to know whether lapses in insurance coverage
would affect the likelihood of completing the HPV vaccine series.
Insurance coverage or gaps in insurance coverage and the source of health care
accessed had not been assessed quantitatively in relation to completion of the HPV
vaccine series among Hispanic adolescent girls. Therefore, the purpose of this study was
to determine if insurance coverage, more specially, gaps in insurance coverage and the
type of medical facility accessed for health care, correlated with low rates of HPV
vaccine series completion among Hispanic adolescent girls. In Chapter 3, I present the
research design and discuss the methodology of the study.
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Chapter 3: Research Method
Introduction
Hispanic adolescent girls are less likely to complete the HPV vaccine series
(Kepka et al., 2015; Roncancio et al., 2017; Walker et al., 2017). Losing insurance
coverage, even for a short time, can have a negative impact on the likelihood of
continued care and preventive service usage (DeVoe et al., 2015). Based on the literature
reviewed, adolescents from racial and ethnic minority groups are more likely to
experience lapse in insurance coverage for extended periods (DeVoe et al., 2015; Gelman
et al., 2013). Prior to this study, the extent to which insurance coverage gaps affect
uptake of the HPV vaccine series had not been explored fully (Cowburn et al., 2013; Lu
et al., 2018). Using provider-verified HPV vaccine data from a nationally representative
sample of Hispanic adolescent girls, I assessed the extent to which discontinuity in
insurance coverage influenced completion of the HPV vaccine series in this study. I also
assessed the ways that gaps in insurance coverage affected Hispanic girls’ access to their
primary care provider for HPV vaccination. The dependent variable in the study was
HPV vaccination status (i.e., being vaccinated or not vaccinated), and the independent
variables were insurance coverage (i.e., insurance status of the adolescent) and the type of
medical facility used to access health care. Covariates included maternal age, family
income, maternal education, and health care provider recommendations.
The purpose of this chapter is to present the study design, methodology, and data
analysis plan that I used to assess the relationship between insurance coverage, type of
medical facility used to access health care, and uptake of the HPV vaccine series. In this
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chapter, I also discuss the target population of interest and the sample size. Because I
analyzed secondary data from the 2016 NIS-Teen were analyzed, I include an
explanation of the original data collection instrument and protocol. In this chapter, I also
explain the ethical procedures relevant to collecting and storing the data,
operationalization of the variables of interest, and relevant threats to the validity of the
study.
Research Design and Rationale
In this study, I used a quantitative, cross-sectional design to assess the relationship
between insurance coverage, source of health care, and completion of the HPV vaccine
series. A cross-sectional research design was appropriate for this study to determine if
there was a relationship between insurance coverage, type of medical facility used to
access health care, and completion of the HPV vaccine series because with this design, it
was possible to assess the nature of the relationship between two or more variables (i.e.,
if changes in one or more of the independent variables was related to changes in the
dependent variable; Setia, 2016). Cross-sectional studies allow researchers to assess the
strength and direction of relationships (Setia, 2016; Thiese, 2014). The cross-sectional
research design allows researchers to measure the exposure and outcome within the
sample simultaneously (Setia, 2016; Thiese, 2014). Although the cross-sectional research
design allows researchers to assess the association between exposure and outcome, it
does not allow researchers to establish any cause and effect between and among variables
(Setia, 2016; Thiese, 2014). For example, if a relationship between insurance coverage
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and HPV vaccination status had been found, it would not have been possible to conclude
that a lack of insurance coverage was the reason for not being vaccinated against HPV.
Methodology
In this section, I explain how the study was conducted and provide information
about the target population, the sample size, and the sampling technique. In this section, I
discussed how the variables of interest were operationalized, the instrument used to
collect the data, and the data analysis plan. In this section, I also discussed threats to
validity of the study and the ethical considerations that are applicable to the study.
Target Population
The target population comprised of Hispanic adolescent girls 13 to 17 years of
age. Approximately 17% of the U.S. populations of children who are younger than 18
years of age are Hispanic (Colby & Ortman, 2014). Of this percentage of Hispanic
children, national data have suggested that more than 70% of them have been and remain
underinsured or uninsured (Gelman et al., 2013; Polonijo & Carpiano, 2013), a situation
that has made them more susceptible to having limited access to preventive care services.
Sampling and Sampling Procedure
In this study, I used secondary data from the 2016 NIS-Teen (CDC, 2016a). As an
adjunct to the NIS-Child, the NIS-Teen is administered to monitor vaccine coverage
among adolescents 13 to 17 years of age (CDC, 2016a). The NIS-Child is conducted
annually and targets households in the United States and select territories with children
19 to 35 months of age (CDC, 2016a). Initially, the households are screened for the
presence of children 19 to 35 months of age and are administered the NIS-Child (CDC,
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2016a). These households are then screened for the presence of adolescents 13 to 17
years of age (CDC, 2016a). If adolescents are present in these households, the parents or
guardians who are the most informed about the adolescents’ vaccination histories are
interviewed (CDC, 2016a). In households with more than one adolescent, one adolescent
between 13 and 17 years of age is randomly chosen to be the subject of the interview
(CDC, 2016a). Household interviews for the 2016 NIS-Teen began on January 14, 2016,
and ended on February 9, 2017, with data being collected from health care providers from
February 2016 to March 2017 (CDC, 2016a). The 2016 NIS-Teen targeted adolescents
born between January 1998 and February 2004, and only participants living in the United
States and select U.S. territories and who were not institutionalized at the time of the
survey were interviewed (CDC, 2016a).
The survey was administered in two phases using random digital dialing (CDC,
2016a). The first phase, the household telephone survey, was administered to respondents
whose telephone numbers were selected randomly from a list of landline and cell phone
numbers (CDC, 2016a). For landline numbers, the telephone survey used quarterly
samples of telephone numbers (CDC, 2016a). Each quarter, the sample of telephone
numbers is updated to reflect new telephone numbers and area codes (CDC, 2016a). For
the cell phone numbers, the respondents were selected randomly from all banks of cell
phone numbers (CDC, 2016a). Each quarter, landline and cell phone numbers are
sampled within estimation areas (CDC, 2016a). For the 2016 administration of the
survey, 61 estimation areas were listed by state or territory (CDC, 2016a).
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Based on this design, each cycle of the survey was estimated to have a specific
degree of precision, meaning that a combination of landline telephone and cell phone
respondents would yield a target of 6.5% coefficient of variation (CDC, 2016a). To
achieve this level of precision, statistical modeling was used to predict the number of
sample telephone numbers (i.e., landline and cell phone numbers) needed to meet this
target (CDC, 2016a). Preliminary analysis of the unweighted 2016 NIS-Teen data files
showed that more than 13 million telephone numbers were screened, and from that
number, 44,771 households with age-eligible adolescents completed the household
interviews (CDC, 2016a). This number included samples from the landline telephone (n =
9,502) and cell phone (n = 35,269) interviews (CDC, 2016a). The 2016 NIS-Teen public
use file that I used in this study comprised data from 43,071 households, excluding
participants from Guam and the U.S. Virgin Islands (CDC, 2016a).
The second phase of the survey involved checking vaccination records with the
respective providers (CDC, 2016a). During the interviews, the parents of the eligible
children were asked to provide the names of the health care providers who administered
the HPV vaccine series to their children (CDC, 2016a). They also were asked for
permission to contact those providers (CDC, 2016a). Once this permission was received
from the respondents, the health care providers were invited to complete immunization
history questionnaires to verify the vaccination information provided by the respondents
(CDC, 2016a). A preview of the data indicated that 33,389 health care providers
completed and returned the immunization history questionnaires and that 20,475 of these
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questionnaires provided adequate vaccine histories relative to the adolescents of interest
(CDC, 2016a).
Sample Size and Power
I used G*power 3.1 (Faul, Erdfelder, Lang, & Buchner, 2013) to calculate the
power needed to detect the likelihood of a statistically significant relationship between
insurance coverage, the type of medical facility used to access health care, and
completion of the HPV vaccine series, if such significance was present. For this analysis,
a compromise power analysis was used; this analysis facilitated calculating the power and
implied alpha, given the sample size, beta/alpha (β/α) ratio, and effect size. For this
study, I based all statistical analyses on weighted data. However, for the purpose of this
power analysis, a subset (n = 1,592) of the data was used for sample size. An odds ratio
(OR) of 1.68 was used in this power analysis. The odds ratio was estimated from previous
studies (Hofman et al., 2013; Okuhara, Ishikawa, Okada, Kato, & Kiuchi, 2018; Pot et
al., 2017) using a small effect size (Cohen’s d) of 0.20, which was equivalent to an
OR = 1.68 (Chen, Cohen, & Chen, 2010).
Type I errors (denoted by α) and Type II errors (denoted by β) are normally
considered serious (Faul, Erdfelder, Buchner, & Lang, 2009; StatPower, n.d.). Type I
errors occur when a null hypothesis is rejected when it is true, and Type II errors occur
when a null hypothesis fails to be rejected when the alternative hypothesis is true
(McCrum-Gardner, 2010). For this analysis, because both types of errors are equally
serious, the β/α ratio was set at 1 rather than some other value like 2, which signifies that
a researcher is 2 times more likely to commit a Type II error over a Type I error. Based
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on the conditions for a compromise power analysis (N = 1,592, β/α ratio = 1, OR = 1.68,
a two-tailed binomial test), I estimated power to be 0.981. This power estimate was
adequate to detect a significant relationship between insurance coverage, the type of
medical facility accessed for health care, and HPV vaccine completion, assuming that
such significance existed.
Access to the Data Set
NIS-Teen data sets are publicly available. Data sets for public use can be
downloaded from the CDC website. In addition to accessing the data set, users also can
access and download all documents associated with the data set, including data
documentation, a codebook, a data user’s guide, a copy of the Household Interview
Questionnaire that was used to collect the data, and the providers’ immunization history
questionnaire (CDC, 2016a). Because the data file was released in a format that was
incompatible with commonly used statistical software, input statements were also
provided to facilitate the transformation of the data into a format that is compatible with
the software used to analyze the data (CDC, 2016a).
The NIS-Teen data are publicly available, and no special permission is required to
use them. However, as per the National Center for Immunization and Respiratory Disease
(NCIRD) and the CDC, users of the NIS-Teen data sets are asked to comply with the
following statements (CDC, 2016a):
1. To only use the data files for analysis and statistical reporting.
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2. If identifying information is inadvertently found, users are prohibited from
using such information and are asked to contact the NCIRD upon such
discovery.
3. Researchers are also prohibited from linking these data files with identifiable
information with other NCIRD or non-NCIRD data files given respondent.
Use of the data signified the researcher’s compliance with the aforementioned statements.
Instrumentation
The NIS-Teen is one of the surveys used by the CDC and NCIRD to monitor
vaccine coverage among adolescents 13 to 17 years of age. After a measles outbreak in
the early 1990s, the CDC (2016a) began using the NIS to track vaccination coverage in
the United States. Since 1994, the NIS has been used to monitor vaccine coverage among
children and adolescents as well as flu vaccination coverage among young children
(CDC, 2016a). The survey is administered annually through telephone interviews to the
parents of eligible adolescents in all 50 states, the District of Columbia, and some U.S.
territories (CDC, 2016a). The NIS-Teen collects and provides the most current
population-based state and local area estimates of vaccination coverage among U.S.
adolescents (CDC, 2016a).
The survey has two parts: Part 1 collects household information, and Part 2
collects vaccination information from health care providers (CDC, 2016a). The
household part of the survey has five sections (CDC, 2016a). Section A, which details
instructions for the screener or the person conducting the interview; Section B, which
collects vaccination information for current vaccines recommended for adolescents as
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well as the flu vaccine; Section C, which collects demographic information; Section D,
which collects health care provider information, and Section E, which collects
information related to health insurance (CDC, 2016a). Part 2, the health care provider
part of the survey, is used to verify vaccination information provided by the parents
during the telephone interviews (CDC, 2016a). Health care providers are asked to
complete information about their practices, services provided, and vaccine-related
information pertaining to the children in question (CDC, 2016a).
Operationalization of Constructs
Insurance coverage was based on the insurance status of eligible Hispanic
adolescents. Individual insurance status was coded “yes” (1) for having insurance
coverage and “no” (0) for having no insurance coverage. Adolescents with insurance
coverage were categorized as having private or public insurance. Being uninsured was
defined as having no insurance coverage (CDC, 2016a).
Continuity in health insurance coverage was measured by periods of “no gap” in
insurance coverage (CDC, 2016b). This included individuals who were currently insured
and were never uninsured. Discontinuous coverage was measured by periods of “gap” in
insurance coverage resulting from the loss of private or public insurance coverage. This
included (a) individuals who were currently insured, but were uninsured at some point;
and (b) individuals who were currently uninsured, but were insured at some point. This
group also includes individuals who were currently uninsured and were never insured for
the period in question.
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Type of medical facility used to access health care was assessed as the facilities
used to access primary care providers. This included public facilities, hospital, private
practices, school-based clinics, and teen clinics (CDC, 2016b). In this study, the facilities
were categorized as public facilities such as public health-operated clinics, hospital-based
clinics, and private practices.
Vaccination status was defined as being immunized against HPV by receiving one
of the three HPV vaccines currently available in the United States (CDC, 2016b).
Vaccination status was defined operationally as whether or not a girl had been fully
vaccinated with one of the recommended HPV vaccines, that is, if she had received all
three doses of the vaccine. A “no” (0) response indicated that the girl had not been
vaccinated, and a “yes” (1) response indicated that the girl had received at least one dose
of the HPV vaccine series.
Data Analysis Plan
Secondary data from the 2016 NIS-Teen were analyzed using SPSS v.25 (IBM
Corporation, 2017). Once the data were downloaded, I reviewed the data set for incorrect
values, duplicated data, or missing data. To simplify the data set, I deleted all variables
that were of no relevance to the study. Missing data were coded as such to ensure that
they were handled appropriately during the analysis. In cases of nonresponses, the
originator of the NIS-Teen data set imputed values to account for the missing data (CDC,
2016a). However, where applicable, missing data were excluded from all statistical
analyses.
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I recoded the variables of interest to the current study to answer the research
questions. In cases where the variables were nominally scaled, the data were unlikely to
have outliers; however, for numerical variables (e.g., age and date, if applicable), the data
were assessed for outliers. As deemed necessary, I removed outliers based on the survey
question being answered. All statistical analyses were based on weighted data. Statistical
significance for all statistical tests was based on the standard alpha value (α = 0.05).
Whether a null hypothesis was accepted or rejected was assessed by the p value. If the p
value was less than or equal to .05, the null hypothesis was rejected in favor of the
alternative hypothesis. The research questions and hypotheses were as follows:
Research Question 1
Research Question 1: Is there a statistically significant relationship between health
insurance coverage and the HPV vaccination status of Hispanic girls?
H01: There is no statistically significant association between health insurance
coverage and the HPV vaccination status of Hispanic girls.
Ha1: There is a statistically significant association between health insurance
coverage and the HPV vaccination status of Hispanic girls.
Health insurance status was operationalized as a nominal variable; insurance
coverage was coded as 1, and no insurance was coded as 0. HPV vaccination status was
operationalized as a nominal variable; vaccinated was coded as 1, and unvaccinated was
coded as 0. The data were analyzed in three stages. For the first stage, univariate analysis
was conducted. At this stage, descriptive statistics of the data were provided. For the
second stage, bivariate analysis was conducted to assess the association between
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insurance coverage and HPV vaccination status. This association was assessed using chisquare tests of association. In addition to chi-square tests, Cramer’s V statistic was
calculated to measure the strength of the relationship between health insurance coverage
and completion of the HPV vaccine series. For the third stage, multiple logistic
regression modeling was used to assess the association between insurance coverage and
HPV vaccination completion, adjusting for maternal age, family income, maternal
education, and health care provider recommendations.
Stepwise regression was used to fit the regression model. Variables were added to
the model using forward selection, which starts with an empty model (i.e., a model with
only the constant) and sequentially adds all of the other variables of interest (i.e., the
independent variables and covariates). The significance of the model was assessed by the
collective effect of the IV, as represented by χ2 coefficient. The Nagelkerke R2 assessed
the variability on the dependent variable that was accounted for by the independent
variable. The Wald coefficient was used to assess the significance of the IV. The
probability that insurance coverage affected HPV vaccination coverage was determined
by odds ratio and was interpreted as follow: An odds ratio value greater than 1.0
indicated an increased chance of completing the HPV vaccine series, and an odds ratio
value less than 1.0 indicated a decreased chance of completing the vaccine series.
Research Question 2
Research Question 2: Is there a statistically significant relationship between the
type of medical facility used to access health care and the HPV vaccination status of
Hispanic girls?
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H02: There is no statistically significant association between the type of medical
facility used to access health care and the HPV vaccination status of Hispanic girls.
Ha2: There is a statistically significant association between the type of medical
facility used to access health care and the HPV vaccination status of Hispanic girls.
Logistic regression was used to assess the extent to which the type of medical
facility used to access health care affected completion of the HPV vaccine series. Type of
medical facility used to access health care was operationalized as a nominal variable and
was assessed based on the facility accessed for care, that is, private and public facilities
or hospital-based clinics. Private facility was coded as 0, public facility was coded as 1,
and hospital-based clinics were coded as 2. HPV vaccination status also was
operationalized as a nominal variable; vaccinated was coded as 1, and unvaccinated was
coded as 0.
I analyzed the data in three stages. For the first stage, univariate analysis was
conducted. At this stage, descriptive statistics of the data were provided. For the second
stage, bivariate analysis was conducted to assess the association between the type of
medical facility used to access health care and HPV vaccination status. This was assessed
using chi-square test of association. In addition to chi-square test, Cramer’s V statistic
was calculated to measure the strength of the relationship between the type of medical
facility used to access health care and completion of the HPV vaccine series. For the third
stage, multiple logistic regression modeling was used to assess the association between
the type of medical facility used to access health care and HPV vaccination completion,
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adjusting for maternal age, family income, maternal education, and provider
recommendation.
Stepwise regression was used to fit the regression model. Variables were added to
the model using forward selection. Forward selection starts with an empty model (i.e., a
model with only the constant) and sequentially adds all the other variables of interest
(i.e., the independent variables and covariates). The significance of the model was
assessed by the collective effect of the independent variables as represented by χ2
coefficient. The Nagelkerke R2 was used to assess the variability on the dependent
variable that was accounted for the independent variable. The Wald coefficient was used
to assess the significance of the independent variable. The probability that the type of
medical facility used to access health care affected HPV vaccination coverage was
determined by odds ratio and was interpreted as follow: An odds ratio value greater than
1.0 indicated an increased chance of completing the HPV vaccine series, and an odds
ratio value less than 1.0 indicated a decreased chance of completing the vaccine series.
Research Question 3
Research Question 3: Is there a statistically significant relationship between health
insurance coverage and the type of medical facility used to access health care, and the
likelihood of completing the HPV vaccine series?
H03: There is no statistically significant association between health insurance
coverage and the type of medical facility used to access health care and the likelihood of
completing the HPV vaccine series.
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Ha3: There is a statistically significant association between health insurance
coverage and the type of medical facility used to access health care and the likelihood of
completing the HPV vaccine series.
Logistic regression was used to test the association between insurance coverage
and the type of medical facility used to access health care, and HPV vaccination status.
Health insurance status was operationalized as a nominal variable; no insurance was
coded as 0, and insurance coverage was coded as 1. Type of medical facility used was
operationalized as a nominal variable and was assessed based on access to private or
public facilities and hospital-based clinics. Private facility was coded as 0; public facility
was coded as 1, and hospital-based clinics were coded as 2. HPV vaccination status was
operationalized as a nominal variable: unvaccinated was coded as 0, and vaccinated was
coded as 1.
The data were analyzed in three stages. For the first stage, univariate analysis was
conducted. At this stage, descriptive statistics of the data were provided. For the second
stage, multivariate analysis was conducted to assess the association between insurance
coverage and the type of medical facility used to access health care, and HPV vaccination
status. This was assessed using multiple logistic regressions. For the third stage, multiple
logistic regression modeling was used to assess the association between insurance
coverage and the type of medical facility used to access health care, and HPV vaccination
completion, adjusting for maternal age, family income, maternal education, and provider
recommendation.

81
In the third stage, stepwise regression was used to fit the regression model.
Variables were added to the model using forward selection, which starts with an empty
model (i.e., a model with only the constant) and sequentially adds all the other variables
of interest (i.e., the independent variables and covariates). The significance of the model
was assessed by the collective effect of the independent variables, as represented by χ2
coefficient. The Nagelkerke R2 assessed the variability on the dependent variable that was
accounted for by the independent variables. The Wald coefficient was used to assess the
significance of the independent variables. The probability that insurance coverage and the
type of medical facility used to access health care affected HPV vaccination coverage
was determined by odds ratio and was interpreted as follow: An odds ratio value greater
than 1.0 indicated an increased chance of completing the HPV vaccine series, and an
odds ratio value less than 1.0 indicated a decreased chance of completing the vaccine
series.
Statistical Assumptions: Chi-Square Test
Three key assumptions were made about the data when conducting a chi-square
test for association. Preliminary investigation of the data was conducted to confirm that
these assumptions were met. For the first and second assumptions, all of the variables
used in this study were nominal variables falling into two or more independent categories
(Laerd Statistics, 2018a). For example, HPV vaccination status had two groups: yes and
no. The variable insurance coverage had two groups (i.e., insured and uninsured), and
type of medical facility had three groups (i.e., private, public, and hospital). The variable
discontinuity in insurance coverage was also consistent with this assumption because it
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had four groups (insured and never uninsured, uninsured and never insured, currently
insured but uninsured at some point, and currently uninsured but insured at some point).
The third assumption (McHugh, 2013) that all expected values should have been greater
than 5 for at least 80% of the cells included in the contingency table was met because all
of the expected values were greater than 5 for chi-square tests of association conducted.
Statistical Assumptions: Multivariate Logistic Regression
Several key assumptions are made about the data when conducting a multivariate
logistic regression (Laerd Statistics, 2018b): (a) The dependent variable should be a
nominal (i.e., categorical) variable; (b) at least one of the independent variables should be
categorical (i.e., ordinal or nominal variable) or continuous (i.e., interval or ratio
variable); (c) the data should have independence of observations and the categories of
dependent variables and independent variables should be mutually exclusive and
exhaustive; (d) there should be no correlation or multicollinearity between the
independent variables; (e) there should be a linear relationship between any continuous
independent variables and the logit transformation of the dependent variable; and (f) the
data set should not contain any outliers or highly influential points (Laerd Statistics,
2018b). Preliminary investigation of the data conducted confirmed that the logistic
regression assumptions were met. The first and second assumptions were met because the
dependent variable of HPV vaccine status was a dichotomous variable (yes/no) and the
independent variables of insurance coverage and type of medical facility were nominal
variables. There was no relationship between observations in the variables of interest
because the categories of the dependent variable and independent variables were
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mutually exclusive and exhaustive, thus satisfying the third assumption. Relative to the
fourth assumption, the variance inflation factor value for the independent variables
ranged from 1.007 to 2.862 suggesting moderate multicollinearity. However, because
these values were below 5, the inclusion of these variables should not affect the
regression model (Akinwande, Dikko, & Samson, 2015; Vatcheva, Lee, McCormick, &
Rahbar, 2016). The fifth assumption presumed that there should have been a linear
relationship between any continuous independent variables and the logit-transformed
dependent variable. Because the independent variables in this study were nominal
variables, this assumption was not jeopardized. Lastly, for the sixth assumption, boxplots
produced by SPSS did not identify outliers in the data set.
Rationale for Inclusion of Covariates
Four covariates were taken into consideration in this study: health care providers’
recommendation, maternal age, maternal education, and family income. Adolescents with
health care providers’ recommendation (Gilkey et al., 2016); higher family income
(Polonijo & Carpiano, 2013); and other maternal-related socioeconomic indicators (e.g.,
age and education) were more likely than individuals without health care providers’
recommendation and individuals with low socioeconomic status to complete the HPV
vaccine series (CDC, 2016a; Fisher et al., 2013; Polonijo & Carpiano, 2013). Because
these covariates were associated with reduced uptake of the HPV vaccine series (Fisher et
al., 2013; Gilkey et al., 2016; Polonijo & Carpiano, 2013), their presence could have
affected the relationships between the variables being evaluated in this study
(Pourhoseingholi, Baghestani, & Vahedi, 2012). Consequently, regression models were
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used to control for any effect that the covariates could have had on the dependent variable
and the independent variables so that the relationships between the dependent variable
and the independent variables was not masked by the presence of the covariates.
Threats to Validity
External Validity
External validity addresses factors within a study that might reduce the
generalizability of the results (Polit & Beck, 2010). Generalizations can be made from
samples to target populations, across populations, over time, and to other settings
(Khorsan & Crawford, 2014). Relative to the current study, generalization of the results
was limited to the design of the study. The NIS-Teen is a cross-sectional survey; hence,
the information gathered from the respondents reflected that time period (i.e., 2016).
Therefore, a study of this nature might not yield the same results a year or even 5 to 10
years from now. Similarly, the target population in the current study were Hispanic girls
13 to 17 years of age, so the results could not be generalized to girls 13 to 17 years of age
from other racial or ethnic groups.
Another threat to the external validity of this study was the effect of the
respondents’ awareness that they were participating in a study. Because of this
awareness, they might have responded in ways based on what they thought were expected
from them rather than what was true. Hence, their responses might have been different
from what they would have been in different settings or contexts.
Internal Validity
Internal validity refers to whether the exposure of interest (i.e., discontinuity in
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insurance coverage or limited access to health care) made a difference on the outcome of
interest (i.e., HPV vaccination status) and whether there was enough evidence to support
such a claim (Sullivan, 2011). Inferences made based on the findings of this study could
have been threatened by the instrument used to measure the variables of interest and by
interviewer effects. The NIS-Teen and other surveys are conducted by the National
Opinion Research Center at the University of Chicago under the direction of the CDC
(CDC, 2016a). The instrument was a pretested, standardized questionnaire that was
administered by highly trained screeners and interviewers, so threats of this nature were
minimized (CDC, 2016a).
Subject effects also can threaten the internal validity of a study. Because the NISTeen is a cross-sectional survey, it could have been subjected to recall bias because the
respondents were asked questions about the vaccination status of adolescents in the
households. The responding parents might have provided information regarding the
children’s vaccination status that might not have been accurate. With the consent of the
parents, health care providers were asked to verify the vaccination status of the children.
In some cases, vaccination status reported by the parents might have been inflated and
might not have matched the providers’ records. Even though provider-verified
vaccination information was crucial to estimating vaccine coverage, discrepancies in
reporting might have gone unresolved because neither health care providers nor parents
were contacted a second time to resolve such issues.
Construct Validity
Construct validity refers to the extent to which an instrument measures the
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construct it is intended to measure (Westen & Rosenthal, 2003). Failure to operationalize
all constructs appropriately can affect the conclusions of any studies. Using a single
construct results in underrepresentation of the construct, making it difficult to assess the
real effect of this construct on the outcome of interest (Westen & Rosenthal, 2003). NISTeen data have been used extensively, and as such, researchers have supported the
robustness of the survey, thus minimizing this threat (CDC, 2016a).
Ethical Considerations
For this study, I used secondary data from the 2016 NIS-Teen that were released
to the public for research purposes. All identifiable information or characteristics were
removed from the data files before they were released to the public. The original
researchers obtained informed consent from the respondent (i.e., the parent, male or
female) who is most knowledgeable of the adolescents’ vaccination histories. Data
collectors were bound by a confidentiality agreement and instructions prohibiting
disclosure of any identifiable information. The data were collected and processed under
high security and strict confidentiality. The data set was used only for research purposes.
Because the 2016 NIS-Teen data set was devoid of any personally identifiable
information, to maintain that confidentiality of the respondents, no attempt was made to
determine or obtain any of their personal identifiable information (Cohen & Mello,
2018).
Metcalf and Crawford (2016) posited that combining different data sets would
result in composite pictures of individuals and reveal their identities. Therefore, the data
set downloaded for this study was not shared with other researchers or combined with
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other data sets in an effort to avoid the risk of invading the privacy of the respondents
(Metcalf & Crawford, 2016). To assure the security of the data, they were stored on a
password-protected external drive that was kept in a safety deposit box (Office of
Research Integrity, n.d.). The data will be kept for 5 years, after which time they will be
destroyed appropriately (Office of Research Integrity, n.d.). Before conducting any part
of this study, formal approval to conduct this study was obtained from Walden
University’s Institutional Review Board (IRB approval #10-10-18-0538888).
Summary
In this study, I used a quantitative, cross-sectional design to assess the relationship
between insurance coverage, the type of medical facility used to access health care, and
completion of the HPV vaccine series by Hispanic girls 13 to 17 years of age. Secondary
data from 2016 NIS-Teen were used to conduct the study. In Chapter 3, I discussed the
research design and the rationale for selecting it. The target population was explained.
The power associated with the sample size available for this study was determined by an
a priori power analysis using G*Power 3.1. How the constructs of interest were
operationalized also was discussed. Logistic regression was used to assess the
significance of the relationship between insurance coverage and the type of medical
facility used to access health care, and completion of the HPV vaccine series. The chapter
concluded with a discussion of the factors that could have threatened the validity of the
study and the ethical procedures that were followed throughout the study. In Chapter 4, I
present the results of the study.
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Chapter 4: Results
Introduction
The purpose of this quantitative cross-sectional study was to assess the extent to
which insurance coverage and the type of medical facility used to access health care
influenced completion of the HPV vaccine series among adolescent Hispanic girls 13 to
17 years of age. Presented in this chapter is a summary of the 2016 NIS-Teen response
rates and the representativeness of the sample from which the data were collected. In this
chapter, I provided a brief description of discrepancies found in data collection, the
descriptive characteristics of the sample, the results of the analyses conducted to answer
each research question, and a summary of the overall findings.
Survey Response Rates
The 2016 NIS-Teen response rate of 32.7% was representative of the total
landline and cell phone numbers sampled (CDC, 2016a). This rate was measured using
the Council of American Survey Research Organization method for telephone surveys
(CDC, 2016a). The Council of American Survey Research Organization methods takes
into consideration the resolution rate for the combined sample (i.e., the number of
households with working residential telephone or active cell phone numbers, the
screening completion rate for the combined sample, and the rate of interviews completed
for eligible households for the combined sample; CDC, 2016a).
Representativeness of the Sample
The NIS-Teen telephone survey was weighted to be representative of all
adolescents 13 to 17 years of age; weights were added as baseline-sampling and provider-
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sampling weights (CDC, 2016a). For baseline-sample weights, because both landline and
cell phone sampling were included in the 2016 NIS-Teen data collected, dual-frame
weights were added to each adolescent with a completed household interview (CDC,
2016a). Dual-frame weights were used to reduce any bias associated with incompleteness
in the landline sampling (CD, 2016a). For provider-sampling weights, weights were
added to each adolescent with adequate provider data (CDC, 2016a).
Discrepancies in Data Collection
The HPV vaccine series is administered as a three-dose series at baseline (0
months), 2 months, and 6 months (CDC, 2017). However, upon review of the 2016 NISTeen data, it became evident that some households had reported that the subject of the
interview received more than the maximum number of doses of the HPV vaccine.
Similarly, a small percentage of the health care provider-verified HPV vaccine
information showed that some adolescents had received more than three doses of the
vaccine. Consequently, I removed cases with more than the required three doses of the
HPV vaccine series from the data set.
Results
Descriptive Characteristics of the Study Sample
The 2016 NIS-Teen data file used for this study comprised data from adolescents
from the United States and selected U.S. territories. The sample comprised 3,744 female
Hispanic adolescents, representing a total of 2,483,816 (weighted) female Hispanic
adolescents. The participants ranged in age from 13 to 17 years (M = 14.97 years,
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SD = 1.399 years). Of the 2,483,816 female Hispanic adolescents who had completed the
household interview, 64% had received a health care provider recommendation for the
vaccine, 26% reported that they did not receive a health care provider recommendation
for the vaccine, and 8% either refused to answer or did not know if the health care
provider recommended the vaccine (see Table 1). Of the 2,483,816 female Hispanic
adolescents, 20% had initiated and completed the HPV vaccine series, 10% did not
complete the vaccine series, and the HPV vaccination status of 70% of the subjects was
not reported. Of the 2,483,816 female Hispanic adolescents who had completed the
health insurance module, 39% had health insurance coverage, 4% had no health insurance
coverage, and 57% of the participants did not respond to this question. Of the 2,483,816
female Hispanic adolescents who completed the health insurance module, 6% had
experienced gaps in insurance coverage at some point since the age of 11 years, 35%
never experienced gaps in insurance coverage, 1% never had insurance, and 58% of the
respondents did not respond to this question.
Relative to the type of medical facility accessed for care, cumulatively, 40% of
the girls in this sample had access to a source of health care, 4% did not identify the
source of health care, and 56% of participants did not complete this question. As the
responding parent, 88% of the mothers were at least 34 years old or older and 12% were
less than 34 years old. Twenty-one percent of the mothers had obtained some level of
college education, 22% had self-identified as college graduates, 26% had completed high
school, and 32% had less than 12 years of school. Twenty percent of the mothers reported
family income greater than or equal to $75,000, 17% had family income between $40,001
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and $75,000, and 51% had family income less than $40,000. Thirteen percent refused to
answer or did not know about the family income.
Table 1
Descriptive and Demographic Characteristics of the Study Sample
Variable
Age of adolescent (years)

Health care provider recommendation

HPV vaccination status

Insurance status

Continuity in health insurance coverage

Type of Medical Facility

Maternal age

Family income

Mother’s education

Category
13
14
15
16
17
Yes
No
Don’t know/Refused
Missing
Yes
No
Missing
Uninsured
Insured
Missing
Currently insured but uninsured at
some point
Currently insured, never uninsured
Currently uninsured but insured at
some point
Currently uninsured, never insured
Missing
Public
Hospital
Private
STD/school/teen clinics/other
facilities
Mixed
Unknown
Missing
< 34 years
34-44 years
45 years and older
< $40,000
$40,000-$75,000
>$75,001
Don’t Know
Refused
Less than 12 years
High school
Some college
College graduate

N
483,561
526,727
542,249
441,275
490,004
1,586,407
636,159
189,870
71,380
500,294
247,783
1,735,739
93,491
966,802
1,423,523
90,065

%
19.5
21.2
21.8
17.8
19.7
63.9
25.6
7.7
2.9
20.1
10.0
69.9
3.8
38.9
57.3
3.6

872,269
62,839

35.1
2.5

30,575
1,428,068
176,298
85,867
511,621
37,721

1.2
57.5
7.1
3.5
20.6
1.5

177,147
96,382
139,781
305,169
1,315,619
863,028
1,254,271
417,269
497,456
200,983
113,837
792,662
642,065
513,532
535,558

7.1
3.9
56.3
12.3
53.0
34.7
50.5
16.8
20.0
8.1
4.6
31.9
25.8
20.7
21.6
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Bivariate Analysis
Results of the Pearson’s chi-square test identified statistically significant
differences in the number of participants who had completed the HPV vaccine series by
health insurance coverage status, χ2 (1, n = 715,277) = 552.40, p < .001 (see Table 2).
This result suggested that girls who were insured were more likely than girls who were
uninsured to complete the HPV vaccine series. However, the association between health
insurance coverage and completion of the HPV vaccine was very weak (Cramer’s V =
.028).
Table 2
Contingency Table for Health Insurance Coverage and HPV Vaccination
Variable
Insurance status

Category
Uninsured
Insured
Total

HPV vaccine up to date
No
Yes
22,213
37,372
213,446
442,246
235,659
479,618

Total
59,585
655,692
715,277

Table 3 shows that completion of the HPV vaccine series was different for girls
who had experienced a gap in insurance coverage and girls who had not. Results of the
Pearson’s chi-square test indicated that this difference was statistically significant, χ2 (1,
n = 514,276) = 5550.35, p < .001. Although the association between continuity in health
insurance coverage and completion of the HPV vaccine series was weak, Cramer’s V =
.104, the results suggested that HPV vaccine series completion was related to continuity
in health insurance coverage.
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Table 3
Contingency Table for Continuity in Health Insurance Coverage and HPV Vaccination
Variable
Continuity of
insurance coverage

Category
No gap in insurance coverage
Yes gap in insurance coverage
Total

HPV vaccine up to date
No
Yes
125,508
297,113
38,821
52,834
164,329
349,947

Total
422,621
91,655
514,276

I conducted a chi-square test of association to assess the relationship between the
type of medical facility accessed for health care and completion of the HPV vaccine
series. Results of Pearson’s chi-square test indicated a statistically significant difference
in the percentage of participants who completed the HPV vaccine series by type of
facility accessed for care, χ2 (2, n = 539,804) = 13903.294, p < .001. This result
suggested that completion of the HPV vaccine series was significantly associated with
having access to a health care facility; however, the association between the type of
medical facility accessed and completion of the HPV vaccine series was small, Cramer’s
V = .160 (see Table 4).
Table 4
Contingency Table for Type of Medical Facility Used to Access Care and HPV
Vaccination
Variable
Type of medical
facility

Category
Public facilities
Private practice
Hospitals
Total

HPV vaccine up to date
No
Yes
48,097
82,791
93,175
48,394
33,126
34,221
174,398
365,406

Total
130,888
341,569
67,347
539,804

Research Question 1 and Hypotheses
Research Question 1: Is there a statistically significant relationship between health
insurance coverage and the HPV vaccination status of Hispanic girls?
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H01: There is no statistically significant association between health insurance
coverage and the HPV vaccination status of Hispanic girls.
Ha1: There is a statistically significant association between health insurance
coverage and the HPV vaccination status of Hispanic girls.
I included HPV vaccination, health insurance coverage, and the covariates of
maternal age, maternal education, family income, and health care providers’
recommendation in the final regression model. The regression results showed that the
addition of HPV vaccination status, health insurance coverage, maternal age, maternal
education, family income, and health care providers’ recommendation significantly
improved the fit between the final model and the data, χ2 (df = 5, n = 709,274) =
38752.04, p < .001. The inclusion of HPV vaccination status, health insurance coverage,
maternal age, maternal education, family income, and health care providers’
recommendation in the final model explained between 5.3% (Cox & Snell R2) and 7.4%
(Nagelkerke R2) of the variance in completing the HPV vaccine series, and the final
model correctly classified 68.6% of the cases.
Table 5 is a summary of the logistic regression coefficient beta (B), the Wald
statistics, the odds ratio, and its 95% confidence interval (CI). Based on Wald statistics,
the covariates of maternal age, maternal education, family income, and health care
providers’ recommendation were significantly associated with completing the HPV
vaccine series (p < .001). After controlling for maternal age, maternal education, family
income, and health care providers’ recommendation in the final model, Hispanic girls
who were uninsured were .878 times less likely to complete the HPV vaccine series (B =
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-.130, OR = .878, 95% CI [.862, .894]) compared to girls who are insured. As family
income increases, the odds of completing the HPV vaccine decreased by .989 (B = -.011,
p < .001; OR = .989, 95% CI [.989, .990]), and not having a health care providers’
recommendation decreased the odds of completing the HPV vaccine series by .988
(B = -.012, p < .001; OR = .988, 95% CI [.988, .988]). As maternal age increases, the
odds of completing the HPV vaccine series increased by 1.0 (B = .024, p < .001;
OR = 1.025, 95% CI [1.016, 1.033]), and as maternal education increases, the odds of
completing the HPV vaccine series increased by 1.3 (B = .268, p < .001; OR = 1.308,
95% CI [1.301, 1.314]). Therefore, I rejected the null hypothesis in favor of the
alternative hypothesis that there is a statistically significant association between health
insurance coverage and completion of the HPV vaccine series after controlling for
maternal age, maternal education, family income, and health care providers’
recommendation.
Table 5
Logistic Regression Results for Completing HPV Vaccine Series Based on Health
Insurance Coverage
Variable
Provider recommendation
Maternal age
Maternal education
Family income
Uninsured

B

SE

-.012
.024
.268
-.011
-.130

.000
.004
.002
.000
.009

Wald
8398.33
36.05
12486.71
12614.82
196.29

df
1
1
1
1
1

Sig.

OR

.000
.000
.000
.000
.000

.988
1.025
1.308
.989
.878

95% CI
Lower Upper
.988
.988
1.016 1.033
1.301 1.314
.989
.990
.862
.894

To expand on the insurance coverage model, I conducted a stepwise multiple
logistic regression using forward selection to assess the significance of the relationship
between continuity in health insurance coverage and completion of the HPV vaccine
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series among Hispanic girls. The regression results showed that the addition of HPV
vaccination status, continuity in health insurance coverage, maternal age, maternal
education, family income, and health care providers’ recommendation to the final model
improved the fit between the final model and the data, χ2 (df = 7, n = 704,805) =
53759.14, p < .001. The inclusion of HPV vaccination status, continuity in health
insurance coverage, maternal age, maternal education, family income, and health care
providers’ recommendation in the final model explained between 7.3% (Cox & Snell R2)
and 10.2% (Nagelkerke R2) of the variance in completing the HPV vaccine series, and the
final model correctly classified 70.5% of the cases.
Table 6 is a summary of the logistic regression coefficients beta (B), the Wald
statistics, the odds ratio, and its 95% CI. Based on Wald statistics, maternal age, maternal
education, family income, health care providers’ recommendation, and continuity in
insurance coverage were significantly associated with completing the HPV vaccine series
(p < .001). After controlling for maternal age, maternal education, family income, and
health care providers’ recommendation, having gaps in insurance coverage significantly
increased the odds of completing the HPV vaccine series.
Compared to girls who were uninsured, girls who were currently insured, but had
been uninsured at some point since 11 years old, were 1.6 times more likely to complete
the HPV vaccine series (B = .460, p < .001; OR = 1.584, 95% CI [1.529, 1.641]).
Likewise, girls who were currently uninsured, but had been insured at some point since
11 years old, were 4.5 times more likely to complete the vaccine series compared to girls
who were uninsured (B = 1.505, p < .001; OR = 4.505, 95% CI [4.333, 4.684]).
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Furthermore, girls who were continuously insured were 3.3 times more likely than girls
who are uninsured to complete the vaccine series (B = 1.205, p < .001; OR = 3.337, 95%
CI [3.232, 3.446]). Maternal age, maternal education, family income, and health care
providers’ recommendation were significantly associated with completion of the HPV
vaccine series. As family income increases, the odds of completing the HPV vaccine
series decreased by .99 (B = -.010, p < .001; OR = .990, 95% CI [990, .990]), and not
having a health care provider recommendation decreased the odds of completing the
vaccine series by .99 (B = -.012, p < .001; OR = .988, 95% CI [.987, .988]). As maternal
age (B = .032, p < .001; OR = 1.033, 95% CI [1.024, 1.041]) and maternal education
increases (B = .257, p < .001; OR = 1.293, 95% CI [1.287, 1.299]), the odds of
completing the HPV vaccine series increased by 1.0 and 1.2, respectively. This result
provided further evidence to support my rejection of the null hypothesis in favor of the
alternative hypothesis that there is a statistically significant association between health
insurance coverage and completion of the HPV vaccine series after controlling for
maternal education, maternal age, family income, and health care providers’
recommendation.
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Table 6
Logistic Regression Results for Completing HPV Vaccine Series Based on Continuity in
Health Insurance Coverage
Variable
Currently insured but uninsured at
some point since age 11
Currently insured and never
uninsured since age 11
Currently uninsured but insured at
some point since age 11
Mother’s age
Mother’s education
Family income
Provider’s recommendation

df

Sig.

OR

652.55

1

.000

1.584

.016

5409.65

1

.000

3.337

3.232

3.446

1.505

.020

5727.82

1

.000

4.505

4.333

4.684

.032
.257
-.010
-.012

.004
.002
.000
.000

60.71
11078.88
9751.79
8902.02

1
1
1
1

.000
.000
.000
.000

1.033
1.293
.990
.988

1.024
1.287
.990
.987

1.041
1.299
.990
.988

B

SE

Wald

.460

.018

1.205

95% CI
Lower Upper
1.529 1.641

Research Question 2 and Hypotheses
Research Question 2: Is there a statistically significant relationship between the
type of medical facility used to access health care and the HPV vaccination status of
Hispanic girls?
H02: There is no statistically significant association between the type of medical
facility used to access health care and the HPV vaccination status of Hispanic girls.
Ha2: There is a statistically significant association between the type of medical
facility used to access health care and the HPV vaccination status of Hispanic girls.
For this research question, I conducted a stepwise multiple logistic regression
using forward selection to assess the significance of the relationship between the type of
medical facility used to access health care and completion of the HPV vaccine among
Hispanic girls. Relative to the type of health care facility accessed, only categories that
were significant contributor to the final model were evaluated. The covariates maternal
age, maternal education, family income, and health care providers’ recommendation
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included in the final regression model were significantly (p ≤ .05) associated with uptake
of the HPV vaccines. The regression results showed that the addition HPV vaccination
status, the type of medical facility accessed, maternal age, maternal education, family
income, and health care providers’ recommendation to the model significantly support
the fit between the final model and the data, χ2 (df = 6, n = 534,300) = 47883.08, p <
.001. However, the addition of HPV vaccination status, the type of medical facility
accessed, maternal age, maternal education, family income, and health care providers’
recommendation to the final model explained between 8.6% (Cox & Snell R2) and 12%
(Nagelkerke R2) of the variance in completing the HPV vaccine series, and 70% of the
cases in the final model were correctly classified.
Table 7 is a summary of the logistic regression coefficients beta (B), the Wald
statistics, the odds ratio, and its 95% CI. Based on Wald statistics, maternal age, maternal
education, family income, and health care providers’ recommendation, and the type of
medical facility accessed were significantly associated with completing the HPV vaccine
series, p < .001. After controlling for maternal age, maternal education, family income,
and health care providers’ recommendation, the type of medical facility, that is, whether
the health care provider was accessible via public facilities (B = .460, p < .001; OR =
1.584, 95% CI [1.553, 1.617]) or private practice (B = .821, p < .001; OR = 2.273, 95%
CI [2.233, 2.314]) increased the odds of completing the HPV vaccine series. As maternal
age (B = .239, p < .001; OR = 1.270, 95% CI [1.258, 1.282]) and maternal education
increases (B = .095, p < .001; OR = 1.100, 95% CI [1.094, 1.107]), the odds of
completing the HPV vaccine series increased by 1.2 and 1.1, respectively. However,
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family income (B = -.013, p < .001; OR = .987, 95% CI [.987, .987]) and health care
providers’ recommendation (B = -.017, p < .001; OR = .983, 95% CI [.983, .983])
decreased the odds of completing the HPV vaccine series. Therefore, I rejected the null
hypothesis in favor of the alternative hypothesis that there is a statistically significant
association between the type of medical facility accessed for health care and completion
of the HPV vaccine series after controlling for maternal age, maternal education, family
income, and health care providers’ recommendation.
Table 7
Logistic Regression Results for Completing HPV Vaccine Series Based on Type of
Medical Facility Used to Access Health Care
Variable
Maternal age
Maternal education
Family income
Provider recommendation
Facility type - public
Facility type - private

B

SE

Wald

df

Sig

OR

.239
.095
-.013
-.017
.460
.821

.005
.003
.000
.000
.010
.009

2506.32
1021.60
13289.29
12215.17
1991.12
8134.15

1
1
1
1
1
1

.000
.000
.000
.000
.000
.000

1.270
1.100
.987
.983
1.584
2.273

95% CI
Lower Upper
1.258
1.282
1.094
1.107
.987
.987
.983
.983
1.553
1.617
2.233
2.314

Research Question 3 and Hypotheses
Research Question 3: Is there a statistically significant relationship between health
insurance coverage, the type of medical facility used to access health care, and the
likelihood of completing the HPV vaccine series?
H03: There is no statistically significant association between health insurance
coverage, the type of medical facility used to access health care, and the likelihood of
completing the HPV vaccine series.
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Ha3: There is a statistically significant association between health insurance
coverage, the type of medical facility used to access health care, and the likelihood of
completing the HPV vaccine series.
Stepwise multiple logistic regression was conducted to assess the significance of
the relationship between health insurance coverage, the type of medical facility used to
access health care and the likelihood of completing the HPV vaccine series among
Hispanic girls. Relative to the type of health care facility accessed, only categories that
were significant contributor to the final model were evaluated. The covariates maternal
age, maternal education, family income, and health care providers’ recommendation
included in the final regression model were significantly (p ≤ .05) associated with uptake
of the HPV vaccines. The regression results showed that the addition of the HPV
vaccination status, health care insurance, the type of medical facility accessed, maternal
education, maternal age, family income, and health care provider recommendation to the
final model significantly improved the fit between the model and the data, χ2 (df = 7,
n = 510,020) = 51595.98 p < .001. The variables in the final model explained between
9.6% (Cox & Snell R2) and 13.5% (Nagelkerke R2) of the variance in completing the
HPV vaccine series, and the final model correctly classified 70.1% of the cases.
Presented in Table 8 is a summary of the logistic regression coefficients beta (B),
the Wald statistics, the odds ratio, and its 95% CI. Wald statistics showed that after
controlling for maternal age, maternal education, family income, and health care
providers’ recommendation, health insurance coverage, more specifically being

102
uninsured, was significantly associated with completing the HPV vaccine series. For girls
who were uninsured, the odds of completing the HPV vaccine series decreased by .942
(B = -.060, p < .001; OR = .942, 95% CI [.921, .963]). The type of medical facility used
to access health care significantly influenced completion of the HPV vaccine series.
Access to a public health care facility (B = .514, p < .001; OR = 1.672, 95% CI [1.637,
1.707]) or a private practice (B = .823, p < .001; OR = 2.277, 95% CI [2.235, 2.319])
increased the odds of completing the HPV vaccine series by 1.67 and 2.27, respectively.
Maternal age, maternal education, family income, and health care providers’
recommendation significantly impacted completion of the HPV vaccine series. Increases
in family income (B = -.014, p < .001; OR = .986, 95% CI [.986, .986]) and lack of a
health care provider recommendation (B = -.018, p < .001; OR = .988, 95% CI [.981,
.982]), decreased the odds of completing the HPV vaccine series. As maternal age
(B = .252, p < .001; OR = 1.286, 95% CI: 1.274, 1.299) and maternal education level
increases (B = .125, p < .001; OR = 1.133, 95% CI [1.126, 1.140]), the odds of
completing the HPV vaccine series increased. Hence, the null hypothesis was rejected in
favor of the alternative hypothesis that there is a statistically significant association
between health insurance coverage, the type of medical facility used to access health care
and the likelihood of completing the HPV vaccine series after controlling for maternal
age, maternal education, family income, and health care provider recommendation.
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Table 8
Logistic Regression Results for HPV Vaccination Based on Discontinuity in Health
Insurance Coverage and Type of Medical Facility Used to Access Health Care
Variable
Maternal Age
Maternal Education
Family Income
Provider Recommendation
Facility type – Public
Facility type – Private
Insurance Status: Uninsured

B

SE

Wald

df

Sig

OR

.252
.125
-.014
-.018
.514
.823
-.060

.005
.003
.000
.000
.011
.009
.011

2598.46
1588.93
14637.87
13043.45
2351.63
7738.53
28.63

1
1
1
1
1
1
1

.000
.000
.000
.000
.000
.000
.000

1.286
1.133
.986
.982
1.672
2.277
.942

95% CI
Lower Upper
1.274 1.299
1.126 1.140
.986
.986
.981
.982
1.637 1.707
2.235 2.319
.921
.963

As indicated in Table 9 below, the addition of continuity in health insurance
coverage to the final model improved the outcome of the relationship between the type of
medical facility used to access health care and completion of the HPV vaccine series.
Results suggested that continuity in insurance coverage and the type of medical facility
used to access health care significantly influenced the likelihood of completing the HPV
vaccine series. Hispanic girls who were continuously insured were 3.5 times more likely
to complete the HPV vaccine series (B = 1.263, p < .001; OR = 3.536, 95% CI [3.400,
3.678]). Similarly, compared to girls who were uninsured, girls who experienced gaps in
insurance coverage were more likely to complete the vaccine series, whether they were
currently insured, but were uninsured at some previous point (B = .180, p < .001; OR =
1.198, 95% CI [1.148, 1.250]), or they were currently uninsured, but were insured at
some previous point (B = 1.480, p < .001; OR = 4.395, 95% CI [4,198, 4,601]). Access to
public health care facilities (B = .699, p < .001; OR = 2.011, 95% CI [1.969, 2.055]) or
private facilities (B = .967, p < .001; OR = 2.654, 95% CI [2.605, 2. 704]) increased the
odds of completing the HPV vaccine series. Maternal age, maternal education, family
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income, and health care providers’ recommendation significantly impacted completion of
the HPV vaccine series. As family income increases (B = -.013, p < .001; OR = .987,
95% CI [.987, .988]) and without a health care provider recommendation (B = -.020, p <
.001; OR = .981, 95% CI [.980, .981]), the odds of completing the HPV vaccine series
decreased. As maternal age (B = .322, p < .001; OR = 1.380, 95% CI [1.366, 1.394]) and
maternal education increases (B = .099, p < .001; OR = 1.104, 95% CI [1.098, 1.111]),
the odds of completing the HPV vaccine series increased. The final model was
statistically significant, χ2 (df = 9, n = 509,014) = 68524.30, p < .001, and it correctly
classified 75% of the cases. The inclusion of continuity in health care insurance, medical
facility type, maternal age, maternal education, family income, and health care provider
recommendation in the final model explained between 12.6% (Cox & Snell R2) and
17.7% (Nagelkerke R2) of the variance in completing the HPV vaccine series. This
provided further evidence in support of rejecting the null hypothesis in favor of the
alternative hypothesis that there is a statistically significant association between health
insurance coverage, the type of medical facility used to access health care, and the
likelihood of completing the HPV vaccine series after controlling for maternal age,
maternal education, family income, and provider recommendation.
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Table 9
Logistic Regression Results for HPV Vaccination Based on Discontinuity in Health
Insurance Coverage and Type of Medical Facility Used to Access Health Care
Variable

B

SE

Wald

Sig

OR

Maternal age
Maternal education
Family income
Provider recommendation
Facility type - public
Facility type - private
Currently insured but uninsured at
some point since age 11
Currently insured and never
uninsured since age 11
Currently uninsured but insured at
some point since age 11

.322
.099
-.013
-.020
.699
.976
.180

.005
.003
.000
.000
.011
.010
.022

4042.633
968.31
11135.20
14237.36
4120.07
10429.09
69.17

1
1
1
1
1
1
1

.000
.000
.000
.000
.000
.000
.000

1.380
1.104
.987
.981
2.011
2.654
1.198

1.263

.020

3956.22

1

.000

3.536

3.400

3.678

1.480

.023

4004.99

1

.000

4.395

4.198

4.601

df

95% CI
Lower Upper
1.366 1.394
1.098 1.111
.987
.988
.980
.981
1.969 2.055
2.605 2.704
1.148 1.250

Summary
In this chapter, weighted data from the 2016 NIS-Teen were evaluated to
determine the extent to which health insurance coverage and the type of medical facility
used to access health care influenced the likelihood of Hispanic female adolescents
completing the HPV vaccine series. In this chapter, I presented the results of the data
analysis conducted to answer the three research questions. The sample comprised data
from 3,744 Hispanic female adolescents that were weighted to represent 2,483,816
Hispanic female adolescents. However, not all survey data were included in the analyses;
missing data were removed from all statistical analyses.
Based on the results of the chi-square tests, completion of the HPV vaccine series
was associated with health insurance coverage and the type of medical facility used to
access health care. In addition to health insurance coverage, continuity in health
insurance coverage was significantly associated with completing the HPV vaccine series.
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The final multiple logistic regression models were used to examine the influence of the
type of medical facility used to access health care and health insurance coverage on HPV
completion status showed that the type of medical facility used to access health care and
health insurance coverage were significantly associated with HPV completion status.
The key findings were that after controlling for maternal age, maternal education,
family income, and health care providers’ recommendation, a statistically significant
relationship was found among completion of the HPV vaccine series, health insurance
coverage, and the type of medical facility used to access health care. Continuity in health
insurance coverage improved the likelihood of completing the HPV vaccine series.
Although Hispanic female adolescents who were uninsured were less likely to complete
the HPV vaccine series, Hispanic female adolescents who are continuously insured were
more likely to complete the vaccine series by accessing their health care providers via
public health care facilities or private practice. Based on the results, the null hypothesis
that there is no significant association between health insurance coverage and the type of
medical facility used to access health care, and completion of HPV vaccine series was
rejected.
Included in Chapter 5 is my interpretation of the findings of this study based on
published research on the effects of health insurance coverage and access to sources of
health care on HPV vaccine uptake among Hispanic female adolescents. In Chapter 5, I
discussed the limitations of the study and the implications for positive social change. I
also provide a detailed description of recommendations for future studies and a
conclusion to complete the chapter.
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Chapter 5: Discussion, Recommendations, and Conclusion
Introduction
Increasing the completion rate of the HPV vaccine series among Hispanic female
adolescents has the potential to significantly reduce HPV infections and the prevalence
and mortality rates of cervical cancer among Hispanic women (Valentino & Poronsky,
2016). Despite the effectiveness of the HPV vaccines and the ACIP’s recommendations
to vaccinate female adolescents, HPV vaccine coverage rates remain low among Hispanic
female adolescents (Jeudin et al., 2014; Markowitz et al., 2014). These low coverage
rates could be related to inadequate insurance coverage and limited access to health care.
In this quantitative cross-sectional study, I evaluated the extent to which health insurance
coverage and access to health care based on the type of medical facility used influenced
completion of the HPV vaccine series among Hispanic female adolescents. The SEM
served as the theoretical framework of the study. The understanding gained from this
study can be used to guide the development of strategies to boost HPV vaccination
coverage among Hispanic female adolescents.
In this study, I evaluated data from the 2016 NIS-Teen to determine the extent to
which health insurance coverage and the type of medical facility used to access health
care influenced the likelihood of Hispanic female adolescents completing the HPV
vaccine series. The results of Pearson’s chi-square tests showed that completion of the
HPV vaccine series was significantly associated with health insurance coverage and the
type of medical facility used to access health care. Likewise, continuity in health
insurance coverage was significantly associated with completing the HPV vaccine series.
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Further analyses using stepwise multiple logistic regression showed that after controlling
for maternal age, maternal education, family income, and health care providers’
recommendation, completion of the HPV vaccine series was significantly associated with
health insurance coverage; more specifically, there was a significant association between
being uninsured and completing the HPV vaccine series.
Interpretation of the Findings
For children from ethnic or racial minorities, Smits-Seemann et al. (2016) found
that gaps in health insurance coverage for any period were associated with either casual
use of or a lack of a usual source of preventive care. However, in the current study, gaps
in insurance coverage did not adversely affect the completion of the HPV vaccine series
by Hispanic female adolescents. Results of multiple logistic regression showed that gaps
in insurance coverage since age 11 years significantly increased the likelihood of
Hispanic female adolescents completing the vaccine series. This result contradicted
Cowburn et al.’s (2014) findings that although there was no association between
insurance coverage and completion of the vaccine series, study participants who were
uninsured for some time were unlikely to initiate the HPV vaccine series. The differences
in association could have been attributed to one of many factors, including, but not
limited to, sampling weights used in the current study and bias in the analyses because of
missing data. The pattern of missing data can substantially result in over- or
underestimation of the odds of completing the HPV vaccine series based on gaps in
insurance coverage. In this analysis, it is possible that the odds ratio for HPV vaccine
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series completion based on gaps in insurance coverage was overestimated, and therefore,
the results were biased away from the null hypothesis.
Results of the multiple logistic regressions showed that there was an association
between the lack of health insurance coverage and completion of the HPV vaccine series.
More specifically, being uninsured decreased the likelihood of Hispanic female
adolescents completing the HPV vaccine series. Conversely, continuous health insurance
coverage increased the likelihood of Hispanic female adolescents completing the HPV
vaccine series. This result confirmed the findings of Reiter et al. (2014), who found that
when compared to Hispanic female adolescents who were insured, those who were
uninsured were less likely to comply with all vaccine requirements, including completion
of the three-dose HPV vaccine series.
Jeudin et al. (2014) identified the lack of insurance as a barrier to HPV
vaccination for girls from ethnic or racial minorities, including Latina girls, who were
less likely to complete the vaccine series. Using data from the 2015 NIS-Teen, Lu et al.
(2018) also showed that, after adjusting for confounding factors, coverage for all
vaccines, including the HPV vaccine series, was lower among adolescents who were
uninsured than for adolescents who were insured. Furthermore, De Jesus and Xiao (2014)
found that continuity in health insurance coverage was predictive of Latinos’ access to
health care services. Although the results of this study confirmed that a lack of insurance
coverage negatively influences the completion of the HPV vaccine series, the low rate of
vaccine completion noted undermined the overall impact of health insurance coverage on
completing the vaccine series. Likewise, although continuous health insurance coverage
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was essential to completing the vaccine series, the high percentage of missing values on
the variables of interest also undermined its impact on completing the vaccine series.
Researchers have concluded that compared to other racial and ethnic groups in the
United States, Hispanics are less likely to use preventive care services (Gelman et al.,
2013; Polonijo & Carpiano, 2013; Velasco-Mondragon et al., 2016). Because Hispanics
have less access to preventive care services or have no access at all, they are more likely
to be underimmunized (Gelman et al., 2013). However, the results of this study did not
support this finding. Instead, the results showed that Hispanic female adolescents with
access to a source of care, whether private or public, have increased odds of completing
the HPV vaccine series. This result was consistent with the findings reported by Test et
al. (2013) that girls with permanent medical homes were more likely to be vaccinated.
Although access to a health care facility can include hospitals, school-based
clinics, and other health care facilities, these facilities were excluded from all statistical
analysis in this study, so their contributions to increasing the rate of HPV vaccine uptake
could not be ascertained. Furthermore, the results of this study confirmed that having
access to a source of health care increased the likelihood of Hispanic female adolescents
completing the HPV vaccine series. However, the high percentage of missing values on
the variable used to assess the type of medical facility used to access health care
minimized the ability to assess the overall impact of the source of health care on
completing the HPV vaccine series.
All of the variables included in the multivariate regression analysis significantly
affected the ability of the final model to assess HPV vaccine completion. The results of
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this study indicated that maternal age and maternal education increased the likelihood of
Hispanic female adolescents’ completing the HPV vaccine series. However, health care
providers’ recommendation and family income decreased their likelihood of completing
the HPV vaccine series.
Researchers have asserted that health care providers’ recommendation is a key
predictor of being vaccinated against HPV (Brewer et al., 2011; Gilkey et al., 2015, 2016;
Holman et al., 2014; Reiter, McRee et al., 2013). In previous studies, Hispanic girls were
found to be less likely to receive a recommendation for the vaccine from their health care
providers and were less likely to receive the HPV vaccine in the absence of such a
recommendation (Gilkey et al., 2015, 2016; Morales-Campos et al., 2013). The results of
my study showed that Hispanic girls are less likely to complete the HPV vaccine series
without a health care provider’s recommendation; however, they also showed that even
though more than 60% of the Hispanic female adolescents in the sample had a provider
recommendation for the vaccine series, only 20% completed the three doses. Therefore,
according to the findings in my study, it appears that a health care provider’s
recommendation does not influence the completion of the HPV vaccine series. It is
probable that the strength of the recommendation may be more influential on completing
the HPV vaccine series; however, this factor was not assessed in this study (see Kester,
Zimet, Fortenberry, Kahn, & Shew, 2013). Receiving a recommendation from health care
providers for the HPV vaccine may be crucial to initiating the vaccine series, but the
factors affecting the completion of the vaccine series may be different from those
required to initiate it (Monnat, Rhubart, & Wallington, 2016). Therefore, as I found in
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this study, the recommendation made by health care providers alone may not be as
influential on HPV vaccine completion as predicted.
Higher family income has been inconsistently associated with HPV vaccine
completion (Gold et al., 2013; Laz et al., 2010; Polonijo & Carpiano, 2013). However,
based on the results of my study, higher family income significantly decreased the odds
of Hispanic female adolescents completing the HPV vaccine series. This finding was
comparable to the results of Walker et al. (2018). Using data from the 2017 NIS-Teen,
these authors found that compared to adolescents with family incomes below the poverty
level, adolescents from families with incomes at or above the poverty level were less
likely to receive all three doses of the HPV vaccine series (Walker et al., 2018). The
finding in the current study is comparable to that of at least one group of researchers;
however, it should be noted that missing values for family income were imputed. Based
on the values imputed, it is probable that girls from families that had incomes at or above
the poverty level were less likely to complete the vaccine series.
I used the SEM as the theoretical framework of this study. This model posits that
intrapersonal factors, interpersonal factors, organizational or institutional factors,
community-related factors, and social factors can influence the risks of a given healthrelated outcome, in this case, not completing the HPV vaccine series (see Baral et al.,
2013; Chimphamba-Gombachika er al., 2012; Nyambe et al., 2016). Although not all of
the factors were evaluated in this study, results showed that maternal education, maternal
age, and family income (i.e., intrapersonal factors); health care providers’
recommendation to get the HPV vaccine series (i.e., interpersonal factors); health care
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providers’ accessibility (i.e., organizational or institutional factors); and insurance
coverage (i.e., community-related factors) influenced the likelihood of Hispanic female
adolescents completing the HPV vaccine series. Although maternal age, maternal
education, continuous health insurance coverage, and access to a source of health care
increased the odds of completing the HPV vaccine series, health care providers’
recommendation and family income decreased the likelihood of completing the vaccine
series. A recommendation from a health care provider is likely to increase the odds of
receiving the HPV vaccine (Gilkey et al., 2015); however, in this study, the lack of such a
recommendation or a casual recommendation reduced the likelihood of receiving the
HPV vaccine.
The HPV vaccine series is one of the most expensive vaccines currently available
in the United States (CDC, 2015b), yet individuals covered by public or private insurance
do not have any financial hindrance to receiving the vaccine. However, for individuals
who are uninsured, are underinsured, or have experienced gaps in insurance coverage,
completion of the HPV vaccine series may be problematic (DeVoe et al., 2015;
Fairbrother et al., 2011). The results of this study confirmed that Hispanic female
adolescents who were uninsured were less likely than Hispanic female adolescents with
continuous insurance coverage to complete the vaccine series. However, I found that gaps
in insurance coverage did not adversely affect completion of the HPV vaccine series.
More research is needed to establish whether gaps in insurance coverage affect vaccine
receipt and completion. Overall, the results of my study corroborated the tenets of the
SEM that different contextual factors influence the risk of a given health-related outcome
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(see Baral et al., 2013; Lanning et al., 2017; Nyambe et al., 2016; Paat, 2013). Because
these factors are interconnected, public health guidelines aimed at addressing the low
uptake of all three doses of the HPV vaccine series should take into consideration
strategies that will create change on different levels.
Limitations of the Study
I used secondary data from the 2016 NIS-Teen. As a result, the evaluations
documented in this study were restricted to questions asked in the survey and were
limited to variables in the NIS-Teen data set. There were high percentages of missing
values for the variables of interest to the study. Therefore, despite adjustment for
nonresponses from health care providers and household interviews and households
without access to telephones or cell phones, the results of the analyses might have been
biased due to the high percentage of missing values. The analyses described in this study
used weighted data, so it is possible that the significance of the associations reported was
overestimated. Missing data can limit the validity of secondary data sources, so given the
high percentage of missing information on the dependent variable and the independent
variables evaluated in this study, the results should be interpreted judiciously.
Recommendations for Future Studies
I evaluated insurance coverage and the type of medical facility used to access
health care in this study to assess the extent to which they affected the completion of the
HPV vaccine series. Given the low vaccine coverage rate reported in this study, more
research may be necessary to identify factors that might be more influential in the uptake
and completion of the HPV vaccine series. In this study, I used secondary data to
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evaluate the relationship between insurance coverage, gap in insurance coverage, the type
of medical facility used to access health care, and completion of the HPV vaccine series.
Hence, the use of instruments more tailored to specifically assessing insurance coverage,
gaps in insurance coverage, and access to a source of health care relative to HPV vaccine
completion is recommended. In light of the conflicting findings regarding the effects of
gaps in health insurance coverage on completion of the HPV vaccine series, further
research is needed to clarify or reduce any ambiguity surrounding the contradicting
findings discussed in this chapter.
Implications for Positive Social Change
Improving the uptake rate of the HPV vaccine series by Hispanic female
adolescents has several implications for positive social change. The cost of the HPV
vaccine series is one of the greatest barriers to its completion, so the results of this study
could help to guide the development of effective strategies to increase HPV vaccination
rates among Hispanic female adolescents by implementing policies that support
continuity in insurance coverage. Streamlining Medicaid policies to renew coverage can
minimize periods of no health coverage for adolescents. Where applicable, provisions
should be made for continued health coverage until renewal conditions are met. Such
provisions would ensure that Hispanic female adolescents could receive the vaccines
promptly and complete the vaccine series in a timely manner.
In the United States, the prevalence of HPV has decreased since the introduction
of the HPV vaccines (Markowitz et al., 2016). This reduction has been partially the result
of adopting various methods designed to raise awareness of HPV, the HPV vaccine
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series, and HPV-related diseases. Relative to social change in the Hispanic community,
heightened awareness could boost the receipt and completion of the HPV vaccines series
by Hispanic female adolescents. Subsequently, this boost in the uptake of the HPV
vaccine series could help to reduce the risk of HPV infections and the incidence of HPVrelated cancers over time.
Each year, public health efforts to prevent cervical cancer save billions of dollars.
It has been estimated that the United States spends more than 80% of its annual budget to
treat and prevent cervical cancer (Coyne-Beasley & Hochwalt, 2016). In Texas, for
example, a state with a high incidence of cervical cancer, within the first year of
diagnosis, more than $60,000 per patient is spent to treat women with cervical cancer
(Lairson et al., 2017). Even though the HPV vaccine does not replace cervical cancer
screening tools and other treatment modalities, completion of the HPV vaccine series not
only could prevent millions of cases of HPV infections, cervical cancer cases, and HPVrelated deaths but could also decrease the economic burden associated with HPV-related
diseases.
Conclusion
As the fourth-leading cause of cancer-related morbidity in the United States,
cervical cancer is preventable through screening and HPV vaccination (ACS, 2017;
Perkins, Lin, Silliman, Clark, & Hanchate, 2015; Van Dyne et al., 2018; Vu, Yu,
Awolude, & Chuang, 2018). Screening through Pap testing is effective in detecting
precancerous lesions; however, a high percentage of Hispanic women diagnosed with
cervical cancer never had a Pap test (ACS, 2017; Kepka et al., 2015). Compared to
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women from other racial and ethnic groups, Hispanic women tend to have the highest
incidence of HPV-related cervical cancer (ACS, 2017). Currently, three HPV vaccines
are available to girls as young as 9 years of age; however, compared to other developing
countries and despite the recommendations of the ACIP, uptake of and completion of the
HPV vaccine series is the lowest in the United States (Rahman, Hirth, & Berenson,
2017). The completion rate is even lower among Hispanic female adolescents (Jemal et
al., 2013). Researchers have asserted that despite having the highest rate of initiating the
HPV vaccine series, Hispanic female adolescents are less likely to complete the vaccine
series (Chou et al., 2011; Jeudin et al., 2014; Niccolai, Mehta, & Hadler, 2011).
From a socioecological perspective, optimizing uptake of the HPV vaccine series
by Hispanic female adolescents may require a concerted effort (Ferrer, Audrey, et al.,
2015; Lanning et al, 2017). In this study I identified several factors that influenced the
completion of the HPV vaccine series among Hispanic female adolescents. After
controlling for maternal age, maternal education, family income, and health care
providers’ recommendation, the type of medical facility used to access health care was
significantly associated with completion of the HPV vaccine series. Similarly, health
insurance coverage and continuity in health insurance coverage were also significantly
associated with completion of the HPV vaccine series. Gaps in insurance coverage did
not adversely affect completion of the HPV vaccine series. However, despite the
significance of the association between the type of medical facility used to access health
care and health insurance coverage, the low rate of HPV vaccine completion noted in this
study indicated that the overall impact of these factors on completion of the vaccine
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series was relatively small. Therefore, although health insurance and a source of health
care are essential to completing the HPV vaccine series, further research is needed to
identify other modifiable contextual factors that may be more influential in completing
the vaccine series.
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